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Concussion	  management	  in	  the	  ED	  is	  inconsistent	  due	  to	  a	  lack	  of	  available	  empirical	  
testing.	  This	  project	  aims	  to	  assess	  the	  feasibility	  of	  a	  large	  multi-­‐centered	  study	  for	  
concussion	  biomarker	  discovery	  in	  the	  ED.	  
This	  prospective	  cohort	  pilot	  and	  feasibility	  study	  was	  conducted	  in	  the	  adult	  and	  
pediatric	  EDs	  of	  an	  urban,	  academic,	  Level	  1	  trauma	  center.	  Twelve	  patients	  with	  
concussions	  and	  twelve	  age-­‐	  and	  gender-­‐matched	  control	  patients	  presenting	  within	  6	  
hours	  of	  an	  injury	  sustained	  during	  recreational	  activity	  were	  enrolled.	  ED	  blood	  
specimens	  were	  banked	  for	  future	  proteomic	  analysis.	  Clinical	  outcomes	  were	  collected	  
via	  online	  survey.	  Patient	  recruitment	  strategies	  were	  refined	  in	  three	  phases:	  (1)	  
identification	  and	  notification	  by	  clinical	  staff,	  (2)	  email	  notification	  automatically-­‐
generated	  by	  the	  electronic	  health	  record	  (EHR),	  and	  (3)	  patient	  financial	  incentives	  
provided	  at	  enrollment	  and	  upon	  completion	  of	  the	  symptom	  diary.	  	  
After	  Phase	  1,	  the	  patient	  identification	  rate	  improved	  from	  0%	  to	  22%	  (p<0.001)	  
with	  EHR-­‐generated	  notifications.	  In	  Phase	  3,	  the	  enrollment	  rate	  improved	  from	  38%	  to	  
100%	  (p=0.01)	  with	  financial	  incentives.	  
This	  pilot	  and	  feasibility	  project	  is	  the	  first	  step	  to	  toward	  the	  goal	  of	  identifying	  new	  
diagnostic	  and	  prognostic	  biomarkers	  as	  well	  as	  novel	  targets	  for	  therapy.	  EHR-­‐based	  
paging	  and	  financial	  incentives	  for	  participation	  increased	  subject	  identification	  and	  
enrollment	  rate	  to	  inform	  and	  optimize	  the	  enrollment	  and	  recruitment	  strategies	  for	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What	  is	  mild	  traumatic	  brain	  injury?	  
Mild	  traumatic	  brain	  injury	  (mild	  TBI	  or	  mTBI)	  is	  an	  alteration	  in	  brain	  function	  
caused	  by	  either	  direct	  head	  trauma	  or	  impulse	  forces	  transmitted	  to	  the	  head.	  	  The	  
injury	  typically	  affects	  memory	  and	  orientation	  and	  may	  involve	  loss	  of	  consciousness	  
(LOC).	  	  It	  can	  also	  be	  associated	  with	  symptoms	  such	  as	  headache,	  difficulty	  
concentrating,	  irritability,	  and	  insomnia.(1)	  The	  terms	  mTBI	  and	  concussion	  are	  often	  
used	  interchangeably	  in	  US	  sports-­‐related	  literature,	  but	  some	  consider	  mTBI	  to	  be	  a	  
more	  severe	  injury	  than	  concussion.	  	  Concussion	  is	  a	  historical	  term	  used	  to	  refer	  to	  
brain	  “shaking”	  and	  resultant	  clinical	  symptoms	  not	  necessarily	  associated	  with	  
pathologic	  injury.(2)	  For	  the	  purpose	  of	  this	  study,	  mTBI	  and	  concussion	  will	  be	  used	  as	  
synonymous	  terms.	  	  The	  most	  widely	  accepted	  sports-­‐related	  definition	  of	  concussion	  in	  
both	  clinical	  and	  research	  settings	  worldwide	  is	  from	  the	  2012	  Zurich	  Consensus	  
Statement	  on	  Concussion	  in	  Sport(2,3):	  
Concussion	  is	  a	  brain	  injury	  and	  is	  defined	  as	  a	  complex	  pathophysiological	  
process	  affecting	  the	  brain,	  induced	  by	  biomechanical	  forces.	  
Several	  common	  features	  that	  incorporate	  clinical,	  pathologic	  and	  biomechanical	  
injury	  constructs	  that	  may	  be	  utilized	  in	  defining	  the	  nature	  of	  a	  concussive	  head	  
injury	  include	  
1.	  Concussion	  may	  be	  caused	  either	  by	  a	  direct	  blow	  to	  the	  head,	  face,	  neck	  or	  





2.	  Concussion	  typically	  results	  in	  the	  rapid	  onset	  of	  short-­‐lived	  impairment	  of	  
neurological	  function	  that	  resolves	  spontaneously.	  However,	  in	  some	  cases,	  
symptoms	  and	  signs	  may	  evolve	  over	  a	  number	  of	  minutes	  to	  hours.	  
3.	  Concussion	  may	  result	  in	  neuropathological	  changes,	  but	  the	  acute	  clinical	  
symptoms	  largely	  reflect	  a	  functional	  disturbance	  rather	  than	  a	  structural	  injury,	  
and	  as	  such,	  no	  abnormality	  is	  seen	  on	  standard	  structural	  neuroimaging	  studies.	  
4.	  Concussion	  results	  in	  a	  graded	  set	  of	  clinical	  symptoms	  that	  may	  or	  may	  not	  
involve	  LOC.	  Resolution	  of	  the	  clinical	  and	  cognitive	  symptoms	  typically	  follows	  a	  
sequential	  course.	  However,	  it	  is	  important	  to	  note	  that	  in	  some	  cases,	  
symptoms	  may	  be	  prolonged.	  
The	  Centers	  for	  Disease	  Control	  and	  Prevention	  (CDC)	  has	  developed	  a	  similar	  
conceptual	  definition	  for	  mild	  TBI(4):	  	  
Occurrence	  of	  injury	  to	  the	  head,	  resulting	  from	  blunt	  trauma	  or	  acceleration	  or	  
deceleration	  forces,	  with	  one	  or	  more	  of	  the	  following	  conditions	  attributable	  to	  
the	  head	  injury	  during	  the	  surveillance	  period:	  	  
●	  Any	  period	  of	  observed	  or	  self-­‐reported	  transient	  confusion,	  disorientation,	  or	  
impaired	  consciousness	  
●	  Any	  period	  of	  observed	  or	  self-­‐reported	  dysfunction	  of	  memory	  (amnesia)	  
around	  the	  time	  of	  injury	  	  
●	  Observed	  signs	  of	  other	  neurologic	  or	  neuropsychological	  dysfunction	  





The	  CDC	  definition	  of	  concussion	  is	  widely	  used	  by	  physicians	  in	  the	  United	  States	  
and	  is	  the	  primary	  definition	  for	  this	  study.	  Per	  the	  CDC	  guidelines,	  symptoms	  associated	  
with	  concussions	  can	  be	  physical	  (e.g.	  headache),	  cognitive	  (e.g.	  fogginess),	  emotional	  
(e.g.	  irritability),	  or	  sleep-­‐related	  (e.g.	  insomnia)	  (Table	  1).	  
Epidemiology	  
Sports-­‐related	  concussions	  have	  traditionally	  received	  little	  attention	  because	  sports	  
culture	  has	  provided	  implicit	  acceptability	  of	  the	  condition.	  	  Players	  are	  celebrated	  for	  
“highlight	  reel”	  hits	  and	  are	  praised	  for	  displays	  of	  “toughness”	  when	  injured	  players	  
remain	  in	  the	  game.	  	  In	  a	  culture	  centered	  on	  playing	  through	  pain,	  concerns	  for	  player	  
safety	  have	  been	  obscured	  by	  the	  desire	  to	  win	  at	  all	  costs.(5)	  A	  recent	  large	  class	  action	  
lawsuit	  between	  retired	  football	  players	  and	  the	  National	  Football	  League	  has	  brought	  
the	  issue	  to	  the	  forefront	  and	  has	  led	  to	  the	  reevaluation	  of	  long-­‐standing	  sporting	  
ideals.(5)	  
Concussions	  account	  for	  approximately	  75%	  of	  TBIs	  each	  year,	  a	  number	  that	  has	  
risen	  due	  to	  increased	  awareness	  and	  reporting	  of	  concussions	  in	  youth	  sports.(6,7)	  
Approximately	  1.4	  to	  3.8	  million	  TBIs,	  including	  concussions,	  occur	  each	  year.(6,8,9)	  This	  
estimate	  includes	  those	  for	  which	  no	  medical	  care	  is	  sought.	  	  In	  youth	  football,	  
concussions	  account	  for	  4-­‐9.6%	  of	  all	  injuries	  with	  increasing	  concussion	  rates	  at	  higher	  
levels	  of	  competition.(5)	  An	  estimated	  182,000	  young	  football	  players	  experience	  at	  
least	  one	  concussion	  each	  year.(5)	  These	  numbers	  are	  probably	  underestimated	  
because	  many	  concussions	  go	  unrecognized.(9)	  Although	  an	  estimated	  5.3	  million	  





epidemic”	  because	  external	  observers	  may	  not	  recognize	  many	  of	  its	  acute	  and	  lasting	  
functional	  alterations	  (e.g.	  memory	  impairment).(6,10)	   
Post-­‐concussive	  syndrome	  
Post-­‐concussive	  syndrome	  (PCS)	  is	  a	  term	  referring	  to	  long-­‐term	  concussion	  
symptoms,	  including	  headache,	  fatigue,	  dizziness,	  irritability,	  and	  insomnia,	  that	  do	  not	  
remit	  in	  the	  immediate	  period	  following	  head	  trauma.	  	  There	  are	  two	  major	  definitions	  
of	  PCS,	  and	  they	  differ	  in	  definition	  of	  concussion,	  timing,	  and	  duration	  of	  symptoms.	  	  In	  
it’s	  definition	  of	  PCS,	  the	  International	  Classification	  of	  Diseases,	  10th	  revision	  (ICD-­‐10)	  
requires	  that	  the	  inciting	  concussion	  include	  LOC	  and	  that	  symptoms	  appear	  within	  four	  
weeks.(11)	  The	  Diagnostic	  and	  Statistical	  Manual	  of	  Mental	  Disorders	  5th	  edition	  (DSM-­‐
V)	  makes	  no	  specific	  mention	  of	  onset	  timing	  and	  does	  not	  specify	  the	  occurrence	  of	  
LOC,	  but	  states	  that	  symptoms	  should	  last	  at	  least	  three	  months.(12)	  
In	  adults,	  concussive	  symptoms	  usually	  resolve	  within	  7-­‐10	  days.(3)	  In	  children,	  
estimates	  of	  symptom	  resolution	  vary	  widely,	  but	  symptoms	  typically	  resolve	  within	  two	  
weeks.	  	  Approximately	  25-­‐35%	  of	  concussion	  patients	  are	  symptomatic	  at	  one	  month	  
and	  less	  than	  5%	  are	  symptomatic	  at	  one	  year.(3)	  Studies	  seeking	  to	  reveal	  risk	  factors	  
predictive	  of	  longer	  duration	  of	  symptoms	  suggest	  that	  psychosocial	  factors	  play	  a	  
significant	  role	  in	  younger	  patients.	  	  Psychological	  traits,	  insufficient	  support	  systems	  
and	  maladaptive	  coping	  strategies	  have	  all	  been	  found	  to	  affect	  PCS	  duration.(13)	  Hou	  
et	  al	  found	  that	  negative	  mTBI	  perceptions,	  perceived	  stress,	  anxiety,	  depression,	  and	  
all-­‐or-­‐nothing	  behavior	  were	  associated	  with	  the	  presence	  of	  PCS	  at	  3	  months	  and	  6	  





Emotional	  and	  neurobehavioral	  dysregulation	  can	  also	  develop	  after	  mTBI	  as	  a	  
consequence	  of	  damage	  to	  the	  orbital	  prefrontal	  cortex.	  	  These	  changes	  in	  emotion	  and	  
cognition	  may	  increase	  the	  risk	  for	  suicidal	  behavior,	  and	  concussions	  have	  been	  
associated	  with	  increased	  rates	  of	  suicide.(15),(16)	  Moreover,	  Hoge	  et	  al	  linked	  mTBI	  
with	  LOC	  to	  increased	  rates	  of	  post-­‐traumatic	  stress	  disorder	  (PTSD)	  and	  depression	  in	  
combat	  veterans.(17)	  	  
Lasting	  manifestations	  of	  concussions	  
In	  the	  days	  following	  a	  concussion,	  the	  brain	  is	  in	  a	  hypermetabolic	  state,	  
predisposing	  it	  to	  repeated	  injury.	  	  If	  concussions	  recur,	  they	  can	  become	  increasingly	  
debilitating.	  A	  study	  of	  high	  school	  athletes	  by	  Collins	  et	  al	  demonstrated	  that	  those	  
with	  three	  or	  more	  prior	  concussions	  have	  increased	  rates	  of	  LOC,	  anterograde	  amnesia,	  
and	  confusion	  with	  subsequent	  concussions.(18)	  A	  recent	  study	  also	  found	  that	  recent	  
or	  repeated	  concussions	  predict	  longer	  PCS	  duration.(19)	  In	  rare	  cases,	  this	  second	  head	  
injury	  can	  lead	  to	  rapid	  onset	  diffuse	  cerebral	  edema.	  	  This	  phenomenon,	  known	  as	  
second	  impact	  syndrome,	  is	  often	  fatal	  and	  can	  cause	  severe	  lasting	  neurologic	  disability	  
in	  those	  who	  survive	  it.(3,20)	  Even	  in	  cases	  where	  a	  second	  concussion	  does	  not	  occur	  in	  
the	  immediate	  post-­‐concussive	  period,	  repetitive	  head	  trauma	  has	  been	  linked	  to	  
neurodegenerative	  disease.	  
Nearly	  a	  century	  ago,	  pathologist	  Harrison	  S.	  Martland	  observed	  chronic	  
neuropsychiatric	  and	  motor	  dysfunction	  in	  former	  boxers.	  	  These	  patients	  displayed	  a	  
clinical	  picture	  including	  personality	  change,	  emotional	  lability,	  memory	  impairment	  and	  





impairment.	  	  Later	  studies	  suggested	  that	  repetitive	  TBI	  from	  boxing	  might	  be	  the	  cause	  
of	  this	  progressive	  neuropathology,	  and	  the	  term	  ‘dementia	  pugilistica’	  was	  coined.(21)	  
Observations	  of	  similar	  neuropsychological	  findings	  in	  participants	  of	  other	  contact	  
sports,	  including	  football,	  hockey,	  and	  wrestling,	  indicated	  that	  this	  disease	  was	  not	  
limited	  to	  boxing.	  	  The	  term	  ‘chronic	  traumatic	  encephalopathy’	  (CTE)	  was	  created	  to	  
characterize	  the	  symptoms	  of	  ‘dementia	  pugilistica’	  and	  reflect	  the	  realization	  that	  head	  
injuries	  from	  all	  forms	  of	  contact	  sports	  can	  cause	  this	  condition.	  Studies	  have	  suggested	  
that	  CTE	  might	  have	  a	  dose-­‐risk	  association,	  with	  increased	  TBI	  exposure	  leading	  to	  
increased	  risk	  of	  impairment.(21)	  The	  neuropathologic	  basis	  of	  CTE	  is	  thought	  to	  stem	  
from	  a	  number	  of	  mechanisms.	  	  Cerebral	  atrophy,	  tau	  abnormalities	  (neurofibrillary	  
tangles),	  aβ amyloid	  plaques,	  and	  neuroinflammation	  all	  possibly	  play	  a	  role.	  However,	  
the	  relatively	  small	  number	  of	  observations	  in	  the	  literature	  have	  not	  been	  able	  to	  
formally	  characterize	  the	  clinical	  and	  pathological	  manifestations	  of	  the	  disease.(21)	  CTE	  
has	  recently	  been	  linked	  to	  a	  series	  of	  homicides	  involving	  NFL	  players	  and	  has	  been	  
shown	  to	  correlate	  with	  increased	  levels	  of	  depression,	  PTSD,	  and	  suicide	  in	  military	  
personnel	  as	  well.(21,22)	  These	  findings	  have	  brought	  attention	  to	  how	  critical	  it	  is	  to	  it	  
increase	  our	  understanding	  of	  TBI-­‐related	  neurodegeneration.	  	  
Current	  guidelines	  on	  return	  to	  play	  
To	  mitigate	  the	  well-­‐documented	  consequences	  of	  recurrent	  concussions,	  graded	  
return	  to	  play	  protocols	  have	  been	  employed	  in	  recent	  years	  to	  prevent	  athletes	  from	  
returning	  to	  the	  field	  before	  their	  concussions	  have	  resolved.	  	  The	  physical	  rest	  





recreational	  activity,	  and	  leisure	  activities	  such	  as	  bike-­‐riding,	  skateboarding,	  and	  
rollerblading.(3)	  Some	  clinicians	  have	  advocated	  “cocoon	  therapy,”	  which	  restricts	  
patients	  to	  a	  darkened	  room	  for	  several	  days	  before	  gradual	  return	  to	  activity;	  but	  this	  
stricter	  protocol	  has	  shown	  no	  additional	  benefit.	  Return	  to	  play	  typically	  does	  not	  occur	  
for	  at	  least	  a	  week	  after	  the	  injury,	  and	  generally,	  no	  athlete	  is	  allowed	  to	  return	  to	  play	  
on	  the	  same	  day	  as	  his/her	  concussion.(23)	  One	  accepted	  graded	  return	  to	  play	  program	  
is	  the	  protocol	  established	  in	  the	  Zurich	  2012	  Consensus	  Statement	  on	  Concussion	  in	  
Sport.(2)	  This	  protocol	  advises	  no	  activity	  initially,	  followed	  by	  aerobic	  activity,	  sports-­‐
specific	  non-­‐contact	  drills,	  full-­‐contact	  practice,	  and	  finally	  a	  full	  return	  to	  play	  (Table	  2).	  	  
Full	  return	  to	  play	  is	  considered	  when	  athletes	  have	  returned	  to	  baseline	  function	  and	  
are	  symptom-­‐free	  at	  each	  step	  of	  the	  graduated	  protocol.	  	  Sport-­‐specific	  return	  to	  play	  
protocols	  have	  also	  recently	  been	  developed	  for	  football,	  basketball,	  baseball,	  softball,	  
soccer,	  wrestling,	  cheerleading,	  lacrosse,	  and	  ice	  hockey.(3)	  
Computerized	  neurocognitive	  tests	  are	  being	  increasingly	  utilized	  to	  diagnose	  and	  
track	  athletes’	  recovery	  from	  mTBI.	  	  These	  tests	  measure	  reaction	  time	  and	  ability	  to	  
process	  information.	  	  The	  most	  common	  of	  these	  tests	  is	  the	  imPACT	  test.	  	  This	  test	  is	  
first	  administered	  to	  the	  athlete	  in	  the	  preseason	  to	  establish	  the	  athlete’s	  
neurocognitive	  baseline	  and	  is	  re-­‐assessed	  after	  a	  head	  injury.	  	  The	  post-­‐injury	  results	  
are	  compared	  to	  the	  baseline	  to	  determine	  if	  a	  concussion	  has	  occurred.	  	  These	  
computerized	  tests	  are	  prone	  to	  false	  negatives	  as	  athletes	  may	  deliberately	  







Trauma	  to	  the	  brain	  triggers	  structural	  changes	  and	  subcellular	  disruptions	  within	  
the	  axon.	  	  One	  of	  the	  first	  changes	  is	  microperforation	  of	  the	  axolemma	  (cell	  membrane	  
surrounding	  an	  axon)	  and	  increased	  membrane	  permeability.	  	  This	  phenomenon	  has	  
been	  observed	  as	  the	  influx	  of	  the	  normally	  excluded	  protein,	  horseradish	  peroxidase,	  
into	  axonal	  cells	  after	  head	  injury.	  	  Extracellular	  calcium	  can	  enter	  through	  the	  disrupted	  
axolemma,	  leading	  to	  caplain	  activation.	  	  Caplain	  is	  a	  calcium-­‐dependent	  protease	  that	  
causes	  cytoskeletal	  changes	  within	  the	  axon	  that	  disrupts	  anterograde	  and	  retrograde	  
transport.	  	  This	  disruption	  can	  lead	  to	  swelling	  of	  contiguous	  axons	  and	  eventual	  
axotomy	  (cutting	  of	  an	  axon).	  	  Disruption	  of	  transport	  may	  also	  be	  mediated	  by	  
microfilament	  compaction	  secondary	  to	  dephosphorylation.(6)	  
Although	  mTBI	  was	  originally	  thought	  to	  be	  an	  exclusively	  acute	  injury,	  there	  is	  
evidence	  showing	  that	  mild	  TBI	  can	  have	  chronic	  effects	  through	  excitotoxicity	  
(neuronal	  damage	  caused	  by	  overactivation	  of	  glutamate	  receptors),	  oxidative	  damage,	  
mitochondrial	  damage,	  blood-­‐brain	  barrier	  breakdown,	  and	  the	  activation	  of	  
inflammatory	  elements.(25,26)	  
Following	  TBI,	  NMDA	  and	  AMPA	  receptors	  can	  be	  over-­‐activated	  by	  glutamate.	  	  
Calcium	  is	  released	  within	  activated	  neurons,	  leading	  to	  enzymatic	  hyperactivity	  and	  
DNA	  fragmentation.(27,28)	  Additionally,	  TBI	  can	  lead	  to	  increased	  levels	  of	  reactive	  
oxygen	  species	  and	  decreased	  levels	  of	  antioxidants.	  	  Mitochondrial	  damage	  results	  





Blood	  brain	  barrier	  (BBB)	  breakdown	  is	  another	  important	  mechanism	  of	  lasting	  
injury	  following	  TBI.	  	  The	  BBB	  consists	  of	  endothelial	  cells	  closely	  associated	  with	  
astrocytes	  and	  glial	  cells.	  	  It	  normally	  keeps	  the	  brain’s	  environment	  free	  of	  blood-­‐borne	  
factors	  and	  immune	  cells.(31)	  Following	  TBI,	  there	  can	  be	  an	  upregulation	  of	  matrix	  
metallopeptidase	  9,	  which	  digests	  tight	  junctions	  and	  disrupts	  proper	  BBB	  function.	  	  
When	  the	  BBB	  breaks	  down,	  leukocytes	  can	  enter	  and	  increase	  the	  osmotic	  forces	  on	  
the	  brain.(32)	  This	  leads	  to	  edema,	  which	  can	  progress	  further	  to	  ischemia,	  cell	  damage,	  
and	  cell	  death.(33)	  
Neuroinflammation	  is	  perhaps	  the	  longest-­‐lasting	  mechanism	  of	  brain	  damage	  
following	  TBI,	  lasting	  for	  up	  to	  17	  years.(34)	  The	  inflammatory	  response	  after	  the	  initial	  
injury	  defends	  the	  site	  from	  invading	  pathogens	  and	  repairs	  the	  damaged	  cells.	  	  
Complement	  activation	  and	  cytokine	  release	  from	  neutrophils,	  monocytes,	  and	  
lymphocytes	  lead	  to	  stimulation	  of	  inflammatory	  cells	  and	  microglia.(25,35)	  Microglia	  
separate	  the	  injured	  tissue	  from	  healthy	  tissue,	  but	  when	  microglial	  activation	  is	  
excessive	  it	  leads	  to	  exaggerated	  proinflammatory	  cytokine	  release	  and	  breakdown	  of	  
the	  BBB.(25,36)	  Astrocytes	  also	  aid	  in	  the	  survival	  of	  neurons	  and	  reduce	  glutamate	  
excitotoxicity.	  	  However,	  by	  isolating	  and	  encapsulating	  axons,	  they	  can	  interfere	  with	  
regeneration	  if	  their	  levels	  are	  too	  high.(36,37)	  	  
Though	  there	  are	  no	  FDA-­‐approved	  pharmaceutical	  interventions	  for	  mTBI,	  potential	  
therapies	  for	  more	  severe	  TBI	  have	  targeted	  some	  of	  the	  aforementioned	  injury	  
mechanisms.	  	  Progesterone,	  a	  neurosteroid	  synthesized	  in	  the	  central	  nervous	  system,	  





protecting	  the	  BBB,	  and	  modulating	  the	  inflammatory	  cascade	  to	  improve	  neuronal	  
survival.(38)	  Progesterone’s	  therapeutic	  role	  is	  controversial,	  however,	  as	  studies	  have	  
shown	  differing	  results	  with	  regard	  to	  mortality	  and	  unfavorable	  outcomes	  following	  
TBI.(38,39)	  Additional	  investigations	  have	  been	  conducted	  on	  neurosteroids	  other	  than	  
progesterone.(39)	  GABAergic	  neurosteroids	  like	  allopregnanolone	  (a	  progesterone	  
metabolite)	  hold	  some	  promise	  due	  to	  their	  ability	  to	  mitigate	  post-­‐injury	  
excitotocicity.(39)	  Further	  investigation	  of	  these	  neurosteroids	  in	  TBI	  is	  warranted	  as	  
questions	  about	  ideal	  dosing	  and	  the	  confounding	  effects	  of	  injury	  heterogeneity	  still	  
exist.(39)	  
Knowledge	  gap	  and	  variation	  in	  concussion	  aftercare	  
Concussions	  are	  often	  diagnosed	  in	  accordance	  with	  institutional	  or	  local	  guidelines.	  
This	  and	  the	  lack	  of	  a	  standardized	  approach	  add	  subjectivity	  and	  variation	  to	  
concussion	  diagnosis.	  	  Using	  the	  Zurich	  Consensus	  definition	  of	  concussion,	  a	  recent	  
study	  at	  a	  level	  I	  trauma	  center	  found	  that	  concussion	  was	  mentioned	  as	  a	  final	  
diagnosis	  in	  only	  31%	  of	  cases.	  	  Concussion-­‐specific	  instructions	  were	  given	  in	  only	  62%	  
of	  ED	  cases	  and	  were	  much	  more	  likely	  to	  be	  given	  if	  there	  was	  LOC.	  	  Activity	  restrictions	  
were	  given	  in	  only	  34%	  of	  cases	  and	  were	  more	  likely	  for	  sports-­‐related	  injury.(40)	  Given	  
the	  risks	  associated	  with	  a	  premature	  return	  to	  play,	  comprehensive	  identification	  of	  
concussion	  patients	  is	  imperative.	  	  Standardization	  relies	  heavily	  on	  the	  accurate	  and	  
consistent	  diagnosis	  of	  the	  condition	  itself,	  which	  in	  turn	  is	  inhibited	  by	  the	  current	  lack	  





One	  of	  the	  likely	  sources	  of	  variation	  in	  concussion	  care	  is	  the	  fact	  that	  concussions	  
are	  diagnosed	  clinically.	  	  Diagnosis	  relies	  more	  on	  subjective	  assessment	  rather	  than	  
objective	  data.	  	  Symptoms	  are	  reported	  by	  athletes	  and	  families	  and	  may	  be	  skewed	  by	  
a	  desire	  for	  social	  acceptance;(5)	  i.e.,	  players	  can	  also	  under-­‐report	  their	  symptoms	  to	  
return	  to	  play	  sooner.	  	  While	  the	  clinical	  symptoms	  of	  acute	  concussion	  can	  be	  
identified	  during	  the	  evaluation	  of	  a	  forthright	  patient,	  the	  potential	  chronic	  symptoms	  
of	  concussion	  might	  not	  appear	  until	  years	  after	  the	  head	  injury.(5)	  When	  these	  delayed	  
symptoms	  present,	  they	  are	  difficult	  to	  link	  to	  the	  inciting	  event.(5)	  
What	  is	  a	  biomarker?	  
Biomarkers	  are	  genes,	  proteins,	  metabolites,	  or	  other	  quantifiable	  physical	  
indicators	  that	  lend	  diagnostic,	  prognostic,	  or	  predictive	  knowledge	  to	  the	  
understanding	  of	  biology	  or	  disease.(41)	  Biomarkers	  have	  been	  identified	  for	  many	  
disease	  states	  including	  troponins	  for	  acute	  coronary	  syndromes,	  LDL	  for	  
hypercholesterolemia,	  and	  p53	  for	  cancer.	  	  	  
The	  biomarker	  hypothesis	  of	  brain	  injury	  suggests	  that	  trauma	  to	  the	  brain	  causes	  
release	  of	  neuronal	  and/or	  glial	  proteins	  into	  biofluids	  (e.g.	  blood,	  CSF,	  urine)	  and	  the	  
levels	  of	  these	  biomarkers	  is	  correlated	  with	  the	  severity	  or	  presence	  of	  injury.	  	  	  
Assessment	  of	  mTBI	  biomarkers	  can	  be	  structured	  around	  three	  fundamental	  points.	  	  
First,	  the	  biomarker	  should	  be	  specific	  to	  the	  brain	  and	  appear	  rapidly	  after	  injury.	  	  
Secondly,	  testing	  for	  the	  marker	  should	  be	  sensitive,	  reliable,	  reproducible	  and	  cost-­‐
effective.	  	  Finally,	  the	  biomarker	  should	  be	  diagnostically	  or	  prognostically	  useful	  or	  





Much	  of	  the	  diagnostic	  challenge	  with	  concussions	  lies	  in	  the	  subjectivity	  of	  self-­‐
reported	  symptoms	  and	  the	  variability	  of	  the	  guidelines	  with	  which	  it	  is	  diagnosed.	  	  The	  
combination	  of	  a	  biomarker	  with	  neurological	  assessment	  could	  overcome	  both	  
problems	  by	  lending	  itself	  to	  an	  empirical	  test	  for	  the	  diagnosis	  or	  prognosis	  of	  
concussions.	  
Most	  promising	  concussion	  biomarkers	  and	  why	  they	  are	  inadequate	  
A	  large	  number	  of	  studies	  have	  sought	  to	  identify	  a	  useful	  biomarker	  for	  mTBI.	  	  
S100b,	  a	  calcium-­‐binding	  protein	  found	  in	  high	  concentrations	  in	  Schwann	  cells	  and	  
astroglial	  cells,	  once	  showed	  significant	  promise.	  S100b	  is	  a	  rapid	  marker	  for	  detection	  
of	  mTBI	  and	  its	  testing	  is	  relatively	  inexpensive.(43)	  However,	  the	  marker	  is	  limited	  in	  its	  
sensitivity.	  Ingebrigtsen	  et	  al	  found	  that	  s100b	  is	  associated	  with	  the	  development	  of	  
symptoms	  in	  only	  67%	  of	  patients	  with	  negative	  CT	  after	  injury.(42,44)	  S100b	  has	  also	  
demonstrated	  limited	  specificity	  due	  to	  peripheral	  sources	  of	  the	  protein.	  	  The	  protein	  is	  
detected	  in	  increased	  concentrations	  in	  multiple	  clinical	  settings,	  including	  minor	  head	  
injury,	  hypoxic	  brain	  injury,	  intracranial	  hemorrhage,	  skull	  fracture,	  brain	  contusion,	  
diffuse	  axonal	  injury,	  and	  stroke.	  	  Furthermore,	  s100b	  is	  not	  a	  reliable	  prognostic	  index	  
because	  even	  very	  elevated	  values	  are	  compatible	  with	  complete	  neurological	  
recovery.(43,45)	  	  	  
Glial	  fibrillary	  acidic	  protein	  (GFAP)	  is	  a	  monomeric	  filament	  protein	  that	  is	  the	  major	  
component	  of	  the	  astrocyte	  cytoskeleton.	  	  It	  is	  found	  exclusively	  in	  the	  central	  nervous	  
system,	  making	  it	  a	  specific	  marker	  of	  central	  nervous	  system	  pathology.	  	  Recent	  studies	  





with	  mild	  and	  moderate	  brain	  injury,	  the	  accuracy	  for	  CT-­‐positive	  injury	  was	  79%,	  with	  a	  
sensitivity	  of	  97%,	  specificity	  of	  18%	  using	  a	  cut-­‐off	  level	  of	  0.035	  ng/mL.(42,46)	  A	  
similar	  study	  in	  a	  pediatric	  cohort	  yielded	  comparable	  results.(47)	  Metting	  et	  al(48)	  
reported	  that	  GFAP	  had	  a	  negative	  predictive	  value	  of	  82%	  for	  MRI	  findings	  3	  months	  
after	  injury,	  showing	  that	  low	  levels	  of	  GFAP	  can	  predict	  normal	  MRI	  results.	  	  In	  a	  
comparison	  study,	  GFAP	  was	  found	  to	  be	  a	  more	  sensitive	  marker	  for	  mTBI	  than	  s100b	  
overall.	  	  However,	  the	  majority	  of	  the	  patients	  with	  mTBI	  in	  the	  study	  had	  no	  detectable	  
GFAP,	  possibly	  indicating	  limited	  specificity	  and	  diagnostic	  utility	  in	  this	  group.(42,48)	  
Neuron-­‐specific	  enolase	  is	  a	  glycolyic	  pathway	  enzyme	  located	  in	  the	  neuronal	  
cytoplasm.	  It	  was	  initially	  found	  to	  be	  expressed	  in	  neurons,	  but	  was	  later	  identified	  in	  
erythrocytes,	  thrombocytes,	  oligodendrocytes,	  and	  neuroendocrine	  cells.	  	  Though	  the	  
marker	  is	  a	  good	  indicator	  of	  mortality	  and	  poor	  outcome	  following	  TBI,	  it	  lacks	  
specificity.	  	  Elevated	  serum	  neuron-­‐specific	  enolase	  is	  a	  marker	  of	  hemolysis,	  small	  cell	  
lung	  cancer,	  neuroendocrine	  bladder	  tumor,	  neuroblastoma,	  and	  ischemic	  stroke.(42)	  
Tau	  is	  a	  microtubule-­‐associated	  axonal	  protein.	  	  Various	  studies	  suggest	  that	  its	  
release	  into	  the	  biological	  fluids	  reflects	  the	  degree	  of	  axonal	  degeneration.	  	  However,	  
multiple	  groups	  have	  provided	  evidence	  that	  tau	  has	  limited	  diagnostic	  value	  for	  mTBI.	  	  
Additionally,	  studies	  by	  Bazarian	  et	  al	  and	  Ma	  et	  al	  both	  suggest	  tau	  does	  not	  have	  
prognostic	  value	  in	  the	  identification	  of	  postconcussive	  syndrome	  either.(42)	  
Conversely,	  a	  recent	  study	  by	  Shahim	  et	  al	  showed	  that	  t-­‐tau	  was	  elevated	  in	  a	  cohort	  of	  





the	  duration	  of	  PCS	  symptoms.(49)	  This	  most	  recent	  data	  is	  promising	  and	  warrants	  
replication	  in	  a	  larger	  cohort	  to	  confirm	  its	  diagnostic	  and	  prognostic	  utility.	  
Calpain-­‐derived	  αII-­‐spectrin	  N-­‐terminal	  fragment	  (SNTF)	  is	  an	  N-­‐terminal	  fragment	  of	  
alpha	  spectrin	  shown	  to	  have	  increased	  accumulation	  in	  damaged	  axons.	  	  It	  is	  
undetectable	  in	  undamaged	  axons,	  but	  is	  generated	  following	  stretch	  injury	  secondary	  
to	  intra-­‐axonal	  calcium	  overload	  and	  spectrin	  proteolysis.(42)	  Siman	  et	  al	  showed	  that	  
an	  elevation	  in	  the	  SNTF	  was	  associated	  with	  changes	  on	  diffusion	  tensor	  imaging	  and	  
was	  correlated	  strongly	  with	  cognitive	  impairment	  that	  lasted	  at	  least	  three	  months.(50)	  
Another	  recent	  study	  quantifying	  SNTF	  levels	  in	  concussed	  hockey	  players	  found	  that	  
SNTF	  levels	  were	  elevated	  at	  several	  time	  points	  from	  one	  hour	  to	  six	  days	  following	  
injury.	  	  SNTF	  had	  particular	  diagnostic	  accuracy	  for	  players	  with	  post-­‐concussive	  
symptoms	  lasting	  at	  least	  six	  days.	  	  At	  the	  one	  hour	  to	  six	  day	  time	  points,	  protein	  levels	  
were	  elevated	  2.5-­‐fold	  in	  players	  with	  symptoms	  lasting	  six	  or	  more	  days.	  	  However,	  
SNTF	  levels	  were	  unchanged	  in	  players	  with	  more	  rapid	  recoveries.(51)	  Though	  
promising,	  SNTF	  might	  lack	  the	  sensitivity	  necessary	  for	  diagnosing	  mild	  concussions.	  	  	  
The	  role	  of	  imaging	  in	  concussion	  management	  
Uncomplicated	  concussion	  involves	  functional	  and	  microstructural	  damage	  not	  
visible	  on	  CT	  scan.(52)	  As	  a	  result,	  CT	  imaging	  has	  no	  role	  in	  the	  diagnosis	  of	  concussion.	  	  
Nevertheless,	  CT	  is	  important	  in	  identifying	  structural	  and	  potentially	  life-­‐threatening	  
diagnoses	  such	  as	  intracranial	  hemorrhage.(53)	  The	  Canadian	  CT	  Head	  Rule	  (CCHR)	  is	  a	  
validated	  clinical	  decision	  rule	  developed	  to	  determine	  when	  CT	  scans	  are	  warranted	  in	  





electroencephalogram	  (QEEG)	  can	  gauge	  small	  abnormalities	  in	  brain	  activity	  associated	  
with	  CT-­‐positive	  mTBI.(54)	  Despite	  the	  availability	  of	  more	  cost-­‐effective	  alternatives,	  CT	  
scans	  are	  still	  overused	  in	  the	  ED.(55)	  
Though	  intracranial	  lesions	  secondary	  to	  mTBI	  can	  be	  missed	  by	  CT	  scans,	  
quantitative	  MR	  methods,	  including	  diffusion	  tensor	  imaging	  (DTI)	  and	  proton	  magnetic	  
resonance	  spectroscopy	  imaging	  (H-­‐MRSI)	  have	  shown	  the	  ability	  to	  detect	  injuries	  
missed	  by	  CT	  and	  other	  conventional	  techniques.	  	  DTI	  has	  been	  able	  to	  uncover	  micro-­‐
structural	  alteration	  in	  axons	  in	  mTBI,	  but	  it	  is	  limited	  by	  the	  fact	  that	  mTBI	  often	  leaves	  
the	  axon	  structurally	  intact	  but	  dysfunctional.(52)	  H-­‐MRSI	  can	  be	  used	  to	  study	  cell	  
status,	  measuring	  such	  parameters	  as	  membrane	  turnover,	  neuronal	  integrity,	  cellular	  
energy/density,	  and	  astroglial	  proliferation.	  	  These	  parameters	  are	  measured	  via	  the	  N-­‐
acetylaspartate,	  creatine,	  choline,	  and	  myoinositol	  markers.	  	  A	  recent	  study	  of	  26	  mTBI	  
subjects	  showed	  that	  these	  patients	  had	  an	  isolated	  decrease	  in	  white	  matter	  N-­‐
acetylaspartate,	  suggesting	  a	  diffuse	  axonal	  dysfuction.(56)	  Given	  that	  N-­‐acetlyaspertate	  
is	  nearly	  100%	  specific	  to	  neurons(57)	  and	  90%	  of	  the	  patients	  in	  the	  study	  had	  an	  
unremarkable	  clinical	  MRI,	  H-­‐MRSI	  could	  be	  both	  a	  sensitive	  and	  specific	  marker	  for	  
mTBI.(52)	  A	  subsequent	  study	  also	  showed	  that	  H-­‐MRSI	  changes	  were	  also	  sensitive	  to	  
PCS	  in	  patients	  with	  normal	  neuroimaging,	  suggesting	  that	  H-­‐MRSI	  might	  also	  have	  
some	  prognostic	  value.(52)	  
Current	  proteomic	  technologies	  and	  their	  limitations	  
Proteomics,	  the	  study	  of	  the	  entire	  complement	  of	  proteins	  produced	  by	  an	  





human	  health	  and	  disease.	  	  The	  human	  proteome	  contains	  an	  estimated	  20,000	  
proteins,	  which	  has	  made	  accurate	  quantification	  of	  biomarkers	  a	  big	  challenge.(58)	  Up	  
until	  recently,	  large	  scale	  proteomic	  profiling	  has	  been	  performed	  using	  mass	  
spectrometry	  and	  antibody–based	  methods.	  	  Though	  mass	  spectrometry	  has	  shown	  
great	  potential	  for	  proteomic	  quantification,	  it	  is	  limited	  by	  a	  lack	  of	  sensitivity,	  
specificity,	  reproducibility,	  and	  throughput.	  Antibody-­‐based	  methods	  such	  as	  enzyme-­‐
linked	  immune-­‐sorbent	  assays	  (ELISA)	  are	  more	  sensitive	  than	  mass	  spectrometry.	  	  
However,	  these	  technologies	  require	  larger	  sample	  sizes	  as	  they	  cannot	  be	  multiplexed	  
above	  a	  few	  simultaneous	  measurements	  because	  secondary	  antibodies	  can	  cross-­‐react	  
with	  surface	  immobilized	  proteins	  including,	  but	  not	  limited	  to,	  primary	  antibodies.	  	  This	  
feature	  of	  antibody-­‐based	  methods	  limits	  their	  specificity.(58)	  
Aptamer-­‐based	  proteomic	  technology	  
Aptamers	  are	  a	  class	  of	  single-­‐stranded	  oligonucleotides	  with	  the	  ability	  to	  bind	  to	  
protein	  targets	  with	  high	  affinity	  and	  specificity.	  	  	  While	  their	  uses	  in	  therapeutics	  and	  
catalysis	  have	  been	  around	  for	  over	  twenty	  years,	  their	  use	  in	  proteomics	  is	  first	  
appeared	  in	  the	  literature	  in	  2010.	  	  Aptamers	  can	  be	  used	  to	  measure	  proteins	  in	  
complex	  matrices	  such	  as	  plasma	  through	  a	  process	  that	  transforms	  protein	  
concentrations	  into	  corresponding	  aptamer	  concentrations.	  	  These	  aptamer	  
concentrations	  are	  quantified	  on	  a	  DNA	  microarray	  (a	  collection	  of	  microscopic	  DNA	  
spots	  attached	  to	  a	  solid	  surface).(58)	  
This	  technology	  is	  capable	  of	  simultaneously	  measuring	  thousands	  of	  proteins,	  and	  





incomplete	  knowledge	  of	  biology.	  	  While	  traditional	  methods	  require	  researchers	  to	  
know	  which	  marker	  they	  plan	  to	  measure,	  aptamer-­‐based	  methods	  can	  act	  as	  a	  
proteomic	  “search	  engine”	  for	  thousands	  of	  low-­‐abundance	  proteins	  in	  body	  fluids.	  	  
Additionally,	  aptamer-­‐based	  proteomic	  technology	  has	  the	  advantage	  of	  measuring	  
proteins	  from	  small	  sample	  sizes	  (as	  low	  as	  15	  microliters)	  and	  with	  high	  
throughput.(58)	  	  	  
Previous	  applications	  of	  aptamer	  technology	  
Early	  applications	  of	  aptamer-­‐based	  technologies	  (SOMAscan,	  SomaLogic,	  Boulder,	  
CO)	  in	  Duchenne	  muscular	  dystrophy	  (DMD),	  Alzheimer’s	  disease,	  tuberculosis,	  
coronary	  heart	  disease,	  and	  pre-­‐term	  birth,	  have	  yielded	  promising	  results.	  	  Duchenne	  
muscular	  dystrophy	  is	  a	  severe	  myopathy	  caused	  by	  a	  lack	  of	  dystrophin	  protein	  
production.(59)	  Unfortunately,	  dystrophin,	  the	  most	  obvious	  DMD	  biomarker,	  is	  
measurable	  only	  though	  invasive	  muscle	  biopsy.	  	  Aptamer-­‐based	  proteomic	  technology	  
has	  identified	  26	  serum	  DMD	  biomarkers.	  	  These	  novel	  biomarkers	  are	  involved	  in	  
muscle	  degeneration,	  inflammation,	  and	  fibrosis	  pathways.(59,60)	  Several	  of	  the	  
biomarkers	  also	  appear	  to	  be	  responsive	  to	  dystrophin	  regeneration.(61)	  In	  the	  field	  of	  
Alzheimer’s	  research,	  aptamer-­‐based	  proteomic	  technology	  has	  found	  several	  
complement	  proteins	  associated	  with	  rapid	  cognitive	  decline(62)	  as	  well	  as	  two	  
modifiable	  markers	  of	  cognitive	  aging.(63)	  In	  a	  Ugandan	  tuberculosis	  study,	  aptamer-­‐
based	  proteomic	  technology	  discovered	  markers	  associated	  with	  both	  tuberculosis	  
treatment(64)	  and	  successful	  treatment	  response	  (defined	  by	  8-­‐week	  culture	  





protein	  biomarker	  panel	  found	  to	  be	  superior	  to	  the	  Framingham	  model	  in	  predicting	  
cardiovascular	  events	  in	  patients	  with	  stable	  coronary	  heart	  disease.(66)	  Recently,	  
aptamer-­‐based	  proteomic	  technology	  was	  also	  used	  to	  confirm	  the	  involvement	  of	  
coagulation	  and	  immune-­‐related	  pathways	  in	  pre-­‐term	  birth.(67)	  
Machine	  learning	  and	  its	  utility	  in	  proteomic	  analysis	  
Many	  scientific	  disciplines	  aim	  to	  model	  the	  relationship	  between	  inputs	  and	  
outputs	  using	  mathematical	  models.	  	  Creating	  these	  models	  becomes	  challenging	  when	  
they	  involve	  complex	  real-­‐world	  phenomena.	  Machine	  learning	  mitigates	  this	  challenge	  
by	  constructing	  algorithms	  that	  can	  learn	  and	  make	  predictions	  from	  data.(68)	  Machine	  
learning	  methods	  have	  been	  used	  to	  develop	  speech	  recognition,	  self-­‐driving	  cars,	  and	  
effective	  web	  searching	  in	  the	  past	  decade	  alone.(69)	  Recent	  advances	  in	  processing	  
capacity	  and	  digital	  data	  gathering	  have	  facilitated	  the	  application	  of	  machine	  learning	  
to	  a	  wide	  array	  of	  fields,	  including	  medical	  diagnosis.	  
Machine	  leaning	  in	  the	  biologic	  realm	  can	  be	  conducted	  in	  either	  a	  supervised	  or	  
unsupervised	  fashion.	  	  “Supervised”	  machine	  learning	  involves	  the	  training	  of	  a	  model	  
based	  on	  samples	  with	  known	  class	  labels	  associated	  with	  them.	  	  “Unsupervised”	  
classification,	  also	  known	  as	  clustering,	  simply	  groups	  samples	  with	  similar	  attribute	  
profiles.(68,70)	  In	  biology,	  researchers	  frequently	  want	  to	  know	  if	  a	  sample	  is	  associated	  
with	  a	  disease	  state.	  	  In	  the	  creation	  of	  a	  model	  that	  can	  accomplish	  this	  task,	  samples	  
can	  be	  labeled	  as	  “diseased”	  or	  “not	  diseased.”	  Supervised	  machine	  learning	  
classification	  uses	  these	  labels	  to	  determine	  variables	  predictive	  of	  classification.	  	  A	  brief	  





(Naïve	  Bayesian	  classifiers,	  rule-­‐based	  learners,	  decision	  trees,	  support	  vector	  machines,	  
and	  artificial	  neural	  networks,	  Figures	  (1-­‐3)	  is	  provided	  below.(70)	  	  
Naïve bayesian classifier model 
Naïve	  Bayesian	  classifiers	  are	  statistical	  methods	  based	  on	  Bayes’	  theorem.	  	  	  Bayes’	  
theorem	  states	  that	  the	  probability	  of	  a	  given	  outcome	  can	  be	  predicted	  by	  the	  
conditions	  surrounding	  the	  outcome.(70)	  The	  conditional	  probability	  is	  given	  by:	  
𝑃(𝐴|𝐵) =
𝑃 𝐵 𝐴 𝑃(𝐴)
𝑃(𝐵) 	  
Where	  A	  represents	  the	  outcome,	  B	  the	  predictor,	  𝑃 𝐵 𝐴 	  the	  conditional	  
probability	  of	  B	  given	  A	  (i.e.	  the	  likelihood),	  P(A)	  the	  probability	  of	  A	  (i.e.	  the	  prior),	  and	  
the	  P(B)	  the	  probability	  of	  the	  predictor	  (i.e.	  the	  evidence).	  	  This	  technique	  is	  efficient	  
and	  trains	  on	  a	  relatively	  small	  number	  of	  outcomes,	  but	  it	  is	  sometimes	  limited	  by	  its	  
assumption	  that	  attributes	  are	  independent	  of	  each	  other.	  	  	  
Random forest model 
Rule-­‐based	  learners	  generate	  sets	  of	  rules	  that	  are	  readable	  by	  humans	  (e.g.	  If	  
attribute	  A<2	  OR	  attribute	  B>4,	  THEN	  Class=1)	  and	  explain	  the	  process	  by	  which	  a	  
sample	  is	  sorted	  into	  a	  particular	  class.	  	  Decision	  trees	  structure	  the	  knowledge	  used	  to	  
discriminate	  samples	  in	  a	  tree-­‐like	  structure.	  Samples	  are	  classified	  by	  following	  the	  tree	  
along	  its	  relevant	  branches.	  	  Branching	  is	  carried	  out	  in	  a	  rule-­‐based	  fashion	  with	  set	  
cutoff	  values.	  	  A	  random	  forest	  builds	  on	  the	  concept	  of	  decision	  trees.	  	  It	  builds	  
multiple	  trees	  from	  a	  data	  set.	  	  Each	  tree	  only	  has	  access	  to	  a	  random	  subset	  of	  
attributes	  from	  the	  samples.	  	  Each	  tree	  predicts	  a	  class,	  and	  the	  class	  chosen	  by	  the	  





Support vector machine model 
Support	  vector	  machines	  predict	  sample	  classes	  based	  on	  the	  concept	  of	  the	  linear	  
separability	  of	  classes	  (Figure	  2).	  	  Support	  vector	  machine	  are	  defined	  by	  the	  criteria	  
they	  use	  to	  create	  the	  optimal	  linear	  classifier	  (the	  classifier	  with	  the	  maximum	  
separation	  between	  classes),	  their	  identification	  of	  the	  minimum	  number	  of	  training	  
instances	  (or	  “support	  vectors”)	  needed	  to	  define	  this	  optimal	  classifier,	  and	  their	  use	  of	  
kernels	  (pattern	  recognition	  algorithms)	  to	  transform	  the	  original	  set	  of	  variables	  into	  a	  
higher	  order	  non-­‐linear	  space	  in	  which	  the	  linear	  separability	  happens.	  	  	  
Artificial neural networks 
Artificial	  neural	  networks	  are	  analogous	  to	  the	  connections	  and	  function	  of	  nerves	  in	  
the	  nervous	  system	  (Figure	  3).	  	  In	  this	  model,	  the	  “neurons”	  are	  computational	  elements	  
(usually	  linear	  classifiers)	  that	  are	  connected	  in	  a	  variety	  of	  ways	  and	  become	  activated	  
or	  deactivated	  based	  on	  the	  signal	  they	  receive.	  	  Though	  each	  linear	  classifier	  used	  in	  
the	  neural	  network	  is	  simple,	  the	  use	  of	  multiple	  neurons	  and	  layers	  allow	  this	  method	  
to	  be	  applied	  to	  complex	  problems.(70)	  
Feature selection in biomarker discovery 
In	  proteomic	  analysis,	  any	  of	  the	  aforementioned	  machine	  learning	  algorithms	  can	  
be	  used	  to	  classify	  biological	  samples.	  	  For	  proteomic	  biomarker	  discovery,	  machine	  
learning	  is	  taken	  one	  step	  further	  -­‐	  the	  researcher	  is	  not	  only	  given	  the	  ability	  to	  classify	  
samples,	  but	  also	  to	  determine	  which	  elements	  within	  a	  sample	  are	  most	  important	  in	  





the	  selection	  of	  the	  most	  significant	  attributes	  within	  a	  sample	  and	  the	  removal	  of	  
redundant	  or	  irrelevant	  attributes.(70)	  	  
Rationale	  for	  assessing	  feasibility	  through	  piloting	  
A	  pilot	  study	  is	  a	  small	  investigation	  that	  tests	  research	  methods	  before	  their	  
implementation	  in	  a	  larger	  study.	  	  The	  purpose	  of	  a	  pilot	  is	  to	  evaluate	  the	  feasibility	  of	  
the	  study’s	  approach.	  	  Prior	  to	  conducting	  a	  large-­‐scale	  investigation,	  a	  researcher	  may	  
choose	  to	  examine	  the	  recruitment,	  retention,	  assessment,	  randomization,	  and	  
implementation	  methods	  of	  the	  study	  to	  make	  sure	  they	  are	  adequate.(71)	  	  	  
It	  is	  important	  to	  note	  that	  a	  pilot	  study’s	  purpose	  is	  not	  to	  test	  a	  statistical	  
hypothesis.	  	  Instead,	  it	  is	  used	  to	  gauge	  the	  probability	  of	  success	  of	  the	  larger	  study	  
given	  a	  set	  of	  procedures	  or	  evaluate	  a	  feasibility	  question	  (e.g.	  determine	  the	  consent	  
proportion).	  	  Since	  a	  pilot	  study	  does	  not	  test	  a	  hypothesis,	  inferential	  statistical	  tests	  
are	  not	  conducted.	  	  Additionally,	  sample	  sizes	  in	  pilot	  studies	  are	  not	  determined	  by	  
power	  calculations,	  but	  rather	  patient	  flow	  and	  budget	  restrictions.(71)	  Though	  there	  
are	  limitations	  to	  the	  role	  and	  interpretation	  of	  pilot	  studies,	  they	  are	  a	  necessary	  first	  
step	  in	  a	  study	  that	  uses	  novel	  methods	  or	  interventions.	  
In	  this	  concussion	  biomarker	  discovery	  project,	  the	  purpose	  of	  a	  pilot	  study	  is	  
twofold.	  	  First,	  piloting	  was	  used	  to	  determine	  the	  typical	  concussion	  patient	  flow	  in	  the	  
ED	  setting	  to	  help	  predict	  recruitment	  and	  enrollment	  rates.	  	  This	  information	  will	  be	  
used	  to	  guide	  RA	  staffing	  decisions	  to	  maximize	  the	  yield	  for	  enrollment.	  By	  assessing	  
the	  reasons	  that	  patients	  were	  excluded	  or	  refused	  participation	  in	  the	  pilot,	  





study	  to	  achieve	  sample	  size	  goals	  and	  desired	  statistical	  power.	  	  Secondly,	  with	  a	  pilot	  
study,	  novel	  biomarkers	  can	  be	  identified	  from	  the	  collected	  samples	  so	  that	  in	  the	  
eventual	  larger	  study,	  less	  expensive	  traditional	  methods	  could	  be	  employed	  to	  assess	  
the	  utility	  of	  those	  biomarkers.	  
Statement of purpose 
Specific	  hypotheses	  of	  the	  thesis 
The	  COMPETE	  protocol	  for	  concussion	  biomarker	  discovery	  in	  the	  emergency	  
department	  (ED)	  is	  feasible	  for	  successful	  subject	  recruitment	  and	  sample	  processing	  
methods.	  
Long-­‐term	  hypothesis	  
Proteins	  not	  normally	  present	  in	  significant	  quantities	  in	  the	  blood	  will	  appear	  
and/or	  become	  elevated	  following	  concussion	  in	  adolescent	  athletes	  but	  not	  following	  
isolated	  extremity	  injury	  in	  age-­‐	  and	  gender-­‐matched	  controls.	  Serum	  levels	  of	  these	  
proteins	  will	  correlate	  with	  concussion	  severity	  and	  time	  to	  resolution	  of	  concussive	  
symptoms.	  
Specific	  aims	  of	  the	  thesis	  
Assess	  the	  feasibility	  of	  a	  study	  protocol	  for	  concussion	  biomarker	  discovery	  in	  the	  
ED.	  	  The	  long-­‐term	  objective	  of	  this	  project	  is	  to	  Identify	  a	  biomarker	  or	  set	  of	  








Twenty-­‐four	  athletes	  between	  the	  ages	  of	  13	  to	  25	  years	  were	  recruited	  from	  the	  
Yale-­‐New	  Haven	  Hospital	  Pediatric	  and	  Adult	  ED	  (urban,	  academic	  Level	  I	  trauma	  center	  
with	  over	  200,000	  patient	  visits	  per	  year	  between	  the	  York	  Street	  and	  Chapel	  Street	  
campuses).	  
Assembling the research team 
A	  research	  team	  was	  assembled	  including	  an	  emergency	  physician	  with	  research	  
expertise	  in	  mTBI	  and	  recruitment	  strategies;	  a	  neurophysiologist	  with	  expertise	  in	  
biomarker	  discovery;	  a	  pediatric	  emergency	  physician	  with	  an	  expertise	  in	  injury;	  and	  a	  
medical	  student	  who	  functioned	  as	  a	  research	  assistant	  (RA),	  responsible	  for	  patient	  
enrollment	  and	  data	  collection.	  
Training 
Prior	  to,	  and	  during	  the	  recruitment	  of	  patients,	  the	  RA	  was	  trained	  in	  research-­‐
related	  clinical	  procedures,	  including	  peripheral	  venous	  phlebotomy,	  urine	  collection,	  
and	  urine	  pregnancy	  testing.	  	  The	  RA	  practiced	  procedures	  through	  formal	  medical	  
school	  training	  as	  well	  as	  supplementary	  training	  by	  hospital	  nursing	  staff.	  	  Whenever	  
possible,	  the	  RA	  carried	  out	  these	  procedures	  on	  study	  recruits.	  
The	  RA	  completed	  training	  in	  the	  use	  of	  OnCore	  (OnCore,	  Forte	  Research	  
Systems,	  Inc.,	  Madison,	  WI),	  an	  electronic	  database	  linked	  to	  the	  Yale-­‐New	  Haven	  





Registration	  in	  this	  system	  ensured	  that	  study	  procedures,	  including	  blood/urine	  
collection	  and	  sample	  processing,	  were	  charged	  to	  a	  research	  account	  and	  not	  to	  the	  
subjects.	  
Subjects/eligibility criteria 
Twelve	  concussion	  patients,	  ages	  13-­‐25	  years,	  presenting	  within	  6	  hours	  of	  a	  mTBI	  
sustained	  during	  recreational	  activity	  were	  enrolled	  prospectively.	  Minor	  head	  injury	  
was	  defined	  as	  a	  blunt	  injury	  associated	  with	  LOC,	  amnesia,	  or	  disorientation	  and	  a	  
Glasgow	  Coma	  Scale	  (GCS)	  score	  of	  13–15.	  	  Since	  we	  sought	  patients	  with	  mTBI,	  there	  
was	  no	  requirement	  for	  subjects	  to	  undergo	  CT	  imaging.	  However,	  if	  a	  subject	  did	  
receive	  CT	  imaging,	  the	  CT	  had	  to	  be	  negative	  for	  structural	  brain	  injury	  (e.g.,	  epidural	  
hematoma).	  Patients	  who	  experienced	  a	  seizure	  following	  their	  injury,	  had	  a	  known	  
bleeding	  disorder	  or	  coagulopathy,	  had	  an	  acute	  focal	  neurological	  deficit,	  or	  were	  
pregnant	  were	  excluded.	  To	  ensure	  no	  pregnant	  patients	  were	  enrolled,	  all	  female	  
subjects	  underwent	  urine	  pregnancy	  testing	  (often	  as	  part	  of	  standard	  care	  in	  the	  ED).	  
Twelve	  age-­‐	  and	  gender-­‐matched	  control	  patients	  presenting	  with	  isolated	  extremity	  
injury	  sustained	  during	  recreational	  activity	  were	  also	  enrolled.	  A	  successful	  age	  match	  
was	  defined	  as	  presentation	  within	  366	  calendar	  days.	  	  Isolated	  extremity	  injury	  was	  
defined	  as	  a	  fracture,	  sprain,	  strain,	  contusion,	  abrasion,	  or	  laceration	  to	  an	  extremity	  in	  







The	  patient	  recruitment	  script	  was	  developed	  to	  standardize	  the	  method	  with	  which	  
patients	  were	  recruited	  (see	  Appendix).	  	  In	  the	  script,	  the	  RA	  introduces	  him/herself	  to	  
the	  subject,	  explains	  the	  study,	  details	  the	  patient’s	  role	  in	  the	  study,	  introduces	  
incentives,	  and	  explains	  the	  patient’s	  right	  to	  refuse	  enrollment	  or	  withdraw	  from	  the	  
study	  at	  any	  time.	  The	  script	  was	  drafted	  by	  the	  RA	  and	  reviewed	  by	  the	  research	  team.	  	  
It	  was	  then	  revised	  based	  on	  how	  well	  it	  supported	  recruitment.	  
Clinical database 
A	  Filemaker	  (Go	  14,	  Filemaker,	  Inc.,	  Santa	  Clara,	  CA)	  data	  collection	  database	  on	  a	  
HIPAA-­‐compliant	  handheld	  tablet	  was	  used	  for	  clinical	  data	  collection.	  	  The	  database	  
included	  inclusion/exclusion	  criteria	  checklists,	  subject	  and	  parent	  consent	  forms	  
(signed	  electronically),	  and	  subject	  questionnaires.	  	  Filemaker	  data	  was	  entered	  on	  a	  
tablet	  computer	  and	  securely	  stored	  on	  a	  HIPAA-­‐compliant	  cloud	  and	  intermittently	  
copied	  to	  a	  spreadsheet	  accessible	  only	  to	  the	  RA	  and	  principal	  investigator.	  
 Development of feasibility study 
While	  conducting	  our	  pilot	  study,	  we	  collected	  feasibility	  data	  in	  the	  following	  areas	  
of	  focus	  –	  “practicality”,	  “adaptation”,	  and	  “limited	  efficacy”	  –	  as	  outlined	  by	  Bowen	  et	  
al.(72)	  “Practicality”	  explored	  the	  extent	  to	  which	  our	  protocol	  could	  be	  carried	  out	  in	  
the	  setting	  of	  limited	  resources,	  time,	  and	  commitment	  from	  ED	  staff.(72)	  “Adaptation”	  
was	  reflected	  in	  our	  focus	  on	  updating	  our	  protocol	  to	  optimize	  recruitment	  
potential.(72)	  “Limited	  efficacy”	  was	  demonstrated	  by	  the	  testing	  of	  our	  protocol	  in	  a	  





with	  intermediate	  rather	  than	  final	  outcomes,	  shorter	  follow-­‐up	  periods,	  and	  our	  study	  
had	  limited	  statistical	  power.(72)	  
Participant	  identification,	  screening,	  and	  recruitment	  
In	  phase	  1	  (first	  35	  days)	  of	  recruitment,	  the	  RA	  posted	  informational	  posters	  in	  the	  
ED	  and	  attended	  morning	  nursing	  staff	  meetings.	  	  Nurses,	  medical	  residents,	  and	  
attending	  physicians	  notified	  the	  RA	  of	  potentially	  eligible	  patients	  via	  telephone	  page.	  	  
In	  phase	  2	  (36	  days),	  eligible	  patients	  were	  identified	  via	  page	  through	  the	  electronic	  
health	  record	  (EHR).	  	  The	  EHR	  automatically	  generated	  a	  page	  to	  the	  RA	  whenever	  a	  
patient	  aged	  13-­‐25	  years	  old	  with	  chief	  complaint	  of	  head	  injury	  presented	  to	  the	  ED.	  	  In	  
the	  final	  phase	  of	  recruitment	  (167	  days),	  patients	  were	  identified	  via	  EHR	  and	  two	  $25	  
incentives	  in	  the	  form	  of	  gift	  cards	  were	  added	  to	  increase	  enrollment	  and	  completion	  
of	  follow-­‐up	  symptom	  diaries.	  
When	  patients	  were	  identified,	  the	  RA	  reviewed	  the	  patient’s	  chart	  for	  the	  purposes	  
of	  obtaining	  information	  about	  the	  injury,	  including	  time	  of	  the	  injury,	  mechanism,	  
location	  and	  site	  of	  the	  injury,	  symptoms,	  and	  any	  relevant	  past	  medical	  history.	  	  With	  
this	  information,	  the	  RA	  determined	  if	  patient	  history	  warranted	  in-­‐person	  screening	  
(i.e.	  the	  patient	  could	  not	  be	  excluded	  based	  on	  this	  initial	  information).	  If	  RA	  was	  
unavailable	  at	  the	  time,	  he	  later	  reviewed	  the	  chart	  to	  determine	  if	  an	  eligible	  patient	  
was	  missed.	  	  Potentially	  eligible	  patients	  were	  screened	  in	  person.	  	  Prior	  to	  consenting	  
patients,	  the	  RA	  verified	  eligibility	  of	  the	  patient	  using	  an	  electronic	  checklist	  on	  a	  





informed	  consent.	  Subjects	  younger	  than	  18	  years	  of	  age	  underwent	  informed	  assent,	  
and	  their	  parent	  or	  guardian	  also	  underwent	  informed	  consent.	  	  
Prior	  to	  recruitment	  of	  controls,	  the	  RA	  met	  with	  triage	  nursing	  staff	  to	  create	  a	  list	  
of	  chief	  complaints	  capable	  of	  encompassing	  most	  of	  the	  extremity	  injuries	  in	  the	  YNHH	  
ED	  (Table	  3).	  	  These	  chief	  complaints	  were	  added	  to	  the	  existing	  head	  injury	  paging	  
system	  during	  the	  final	  recruitment	  phase.	  	  	  
Data	  collection	  
After	  the	  consenting	  process,	  demographic	  information	  including	  race,	  ethnicity,	  
insurance	  type,	  and	  education	  level	  was	  collected.	  	  Patients	  also	  provided	  detailed	  
clinical	  information	  that	  served	  as	  the	  acute	  post-­‐injury	  data	  point	  (Figure	  4).	  	  The	  data	  
collection	  inventory	  used	  in	  the	  ED	  and	  follow-­‐up	  was	  based	  on	  the	  U.S.	  Military	  
Neurobehavioral	  Symptom	  Checklist.(73)	  Clinical	  data	  collected	  included:	  









• Loss	  of	  balance	  
• Coordination	  
• Mood	  change	  
• Vision	  change	  
• Light	  sensitivity	  
• Hearing	  difficulty	  
• Sensitivity	  to	  noise	  
• Body	  numbness	  or	  tingling	  
• Changes	  in	  taste	  and/or	  smell	  
• Concentration	  
• Forgetfulness	  
• Difficulty	  making	  decisions	  
• Slowed	  thinking	  
• Fatigue	  
• Date/time	  of	  symptom	  resolution	  (if	  
applicable	  








Specimen	  collection	  and	  processing	  
The	  RA	  collected	  3	  mL	  blood	  and	  10	  mL	  urine	  specimens.	  If	  the	  subject	  was	  already	  
scheduled	  to	  undergo	  phlebotomy	  as	  part	  of	  his/her	  ED	  evaluation,	  an	  additional	  tube	  
of	  blood	  was	  drawn	  for	  the	  study	  and	  collected	  in	  a	  heparinized,	  lavender	  EDTA	  tube.	  If	  
the	  subject	  was	  not	  scheduled	  for	  phlebotomy	  as	  part	  of	  their	  ED	  evaluation,	  blood	  was	  
collected	  by	  venous	  blood	  draw	  for	  the	  study’s	  purposes	  only.	  	  When	  patient	  
venipuncture	  was	  difficult	  to	  perform,	  the	  RA	  elicited	  assistance	  from	  nursing	  and/or	  
technical	  staff.	  Mid-­‐stream	  urine	  specimens	  were	  collected	  in	  sterile	  urine	  collection	  
cups.	  	  Samples	  were	  coded	  at	  the	  time	  of	  collection.	  
Blood	  and	  urine	  specimens	  were	  sent	  to	  the	  Yale-­‐New	  Haven	  Hospital	  laboratory	  
after	  collection.	  	  There,	  blood	  tubes	  were	  sealed	  and	  centrifuged	  (at	  room	  temperature	  
2200	  x	  g	  for	  15	  minutes).	  	  Serum	  was	  drawn	  off,	  aliquoted,	  and	  frozen	  at	  -­‐20ºC.	  	  Urine	  
samples	  were	  frozen	  (at	  -­‐20ºC).	  	  Within	  the	  next	  24	  hours,	  the	  RA	  transported	  the	  
specimens	  on	  dry	  ice	  to	  an	  outside	  laboratory.	  	  Here,	  the	  samples	  were	  frozen	  and	  
stored	  at	  -­‐80ºC.	  	  For	  proteomic	  analysis	  (pending	  at	  this	  time),	  all	  samples	  will	  be	  
express	  mailed	  on	  blue	  ice	  to	  Somalogic.	  	  
Lab	  communications	  
In	  this	  study,	  direct	  communication	  with	  lab	  staff	  was	  essential	  to	  daily	  operations.	  	  
Prior	  to	  beginning	  the	  study,	  protocols	  were	  reviewed	  and	  approved	  by	  lab	  
administrators	  and	  billing	  was	  arranged	  through	  OnCore.	  	  After	  collection,	  study	  
samples	  were	  sent	  to	  the	  hospital	  chemistry	  lab	  through	  a	  tube	  system	  along	  with	  a	  





Committee	  number	  assigned	  to	  the	  study	  and	  included	  the	  details	  for	  specimen	  
processing	  and	  handling.	  	  In	  the	  early	  stages	  of	  the	  study,	  the	  RA	  called	  lab	  technicians	  
directly	  to	  confirm	  their	  understanding	  of	  the	  research	  protocol.	  	  After	  samples	  were	  
frozen	  overnight,	  the	  RA	  contacted	  lab	  staff	  in	  a	  designated,	  outside	  research	  lab	  to	  set	  
up	  a	  transport	  time.	  	  	  
Outcome	  measures	  
The	  primary	  outcome	  measure	  for	  the	  eventual	  machine	  learning	  analysis	  will	  be	  the	  
presence	  or	  absence	  of	  clinical	  head	  injury.	  Proteins	  will	  be	  pursued	  as	  biomarkers	  if	  
their	  concentration	  in	  the	  blood	  or	  urine	  of	  the	  concussion	  subjects	  is	  greater	  than	  in	  
controls	  by	  two	  standard	  deviations.	  Approximately	  1300	  proteins	  will	  be	  assessed.	  	  The	  
secondary	  outcome	  measure	  will	  be	  time	  to	  full	  recovery	  of	  concussion	  symptoms.	  	  	  
Follow-­‐up	  survey	  
Follow-­‐up	  was	  conducted	  through	  electronic	  surveys	  emailed	  to	  patients	  using	  the	  
Qualtrics	  Survey	  Tool	  (Qualtrics,	  LLC,	  Provo,	  UT,	  Figure	  5).	  Patients	  provided	  contact	  
information	  in	  the	  ED	  and	  the	  RA	  contacted	  subjects	  and/or	  parents	  at	  regular	  intervals	  
by	  phone	  call	  or	  text	  message	  to	  remind	  them	  to	  complete	  surveys	  on	  follow-­‐up	  days.	  	  A	  
$25	  gift	  card	  incentive	  was	  sent	  to	  patients	  upon	  completion	  of	  follow	  up.	  	  Follow-­‐up	  
surveys	  included	  the	  same	  clinical	  questions	  as	  the	  initial	  inventory,	  but	  also	  inquired	  
about	  how	  symptoms	  affected	  patients’	  daily	  lives	  and	  how	  others	  perceived	  the	  





Consideration	  for	  timing	  of	  follow-­‐up	  
Patient	  follow-­‐up	  for	  head	  injury	  patients	  was	  conducted	  at	  24-­‐72	  hours	  after	  injury,	  
one	  week	  after	  injury,	  and	  then	  one,	  three,	  and	  six	  months	  after	  the	  injury	  to	  assess	  for	  
symptoms	  after	  the	  ED	  visit.	  	  Head	  injury	  patients	  were	  followed	  until	  they	  were	  
symptom	  free	  for	  two	  consecutive	  checkpoints	  (or	  for	  six	  months	  if	  symptoms	  persisted	  
for	  that	  long).	  For	  control	  patients,	  follow-­‐up	  was	  conducted	  at	  24-­‐72	  hours	  after	  injury	  
and	  one	  week	  after	  injury	  to	  ensure	  that	  no	  head	  injury	  symptoms	  were	  present	  in	  
these	  patients.	  
Although	  concussions	  typically	  resolve	  within	  two	  weeks	  in	  pediatric	  populations,	  
and	  even	  sooner	  in	  adult	  populations,(3)	  symptoms	  can	  last	  up	  to	  a	  year	  in	  a	  small	  
subset	  of	  patients.(3)	  To	  capture	  the	  most	  salient	  data	  points,	  follow-­‐ups	  were	  
frontloaded	  and	  continued	  for	  many	  months.	  
Recruitment	  goal	  
This	  was	  a	  pilot	  study,	  so	  power	  calculations	  were	  not	  used	  to	  determine	  the	  sample	  
size	  or	  recruitment	  goal.	  	  The	  sample	  size	  was	  instead	  based	  on	  the	  batching	  logistics	  of	  
proteomic	  analysis.	  	  To	  eliminate	  the	  “batch	  effect,”	  i.e.	  systematic	  error	  introduced	  
when	  microarray	  data	  is	  processed	  in	  multiple	  batches,	  the	  whole	  study	  was	  processed	  
in	  a	  single	  batch.(74)	  The	  batch	  size	  for	  the	  assay	  was	  24,	  and	  this	  number	  was	  divided	  
into	  twelve	  experimental	  subjects	  and	  twelve	  controls.	  	  The	  choice	  of	  one	  batch	  of	  data	  
over	  multiple	  batches	  was	  also	  influenced	  by	  budget	  limitations.	  	  Findings	  from	  the	  






The	  feasibility	  of	  the	  study	  methods	  was	  determined	  by	  the	  ability	  of	  the	  research	  
team	  to	  optimize	  recruitment	  within	  the	  study	  period.	  	  Feasibility	  findings	  from	  this	  pilot	  
study	  will	  inform	  staffing	  needs	  for	  the	  subsequent,	  larger	  and	  adequately	  powered	  
study.	  	  As	  the	  frequency	  of	  sports-­‐related	  concussion	  is	  dependent	  on	  the	  scheduling	  of	  
recreational	  activities,	  clinical	  data	  including	  date	  and	  time	  of	  arrival	  in	  the	  ED	  was	  
collected	  to	  determine	  when	  best	  to	  staff	  for	  and	  recruit	  future	  patients.	  
Data	  and	  safety	  monitoring	  
The	  Human	  Investigation	  Committee	  of	  Yale	  University	  reviewed	  and	  approved	  the	  
study	  (protocol	  #1503015422).	  	  After	  a	  patient	  was	  deemed	  eligible	  for	  the	  study,	  if	  the	  
subject	  was	  not	  a	  minor,	  the	  patient	  was	  approached	  to	  obtain	  informed	  consent	  in	  the	  
patient’s	  room	  within	  the	  ED.	  	  If	  the	  subject	  was	  a	  minor,	  informed	  assent	  from	  the	  
patient	  and	  parental	  permission	  were	  solicited.	  	  Minor	  patients	  did	  not	  require	  re-­‐
consent	  after	  reaching	  the	  age	  of	  majority	  during	  the	  time	  of	  enrollment.	  
This	  was	  a	  minimal	  risk	  study,	  which	  targeted	  populations	  wherein	  impaired	  
decision-­‐making	  capacity	  was	  unlikely	  (minor	  head	  injury	  only).	  During	  the	  consent	  
process	  (and	  throughout	  the	  trial),	  research	  staff	  educated	  parents	  and	  patients	  about	  
concussions	  and	  how	  clinical	  trials	  work.	  Potential	  risks	  were	  enumerated	  and	  described	  
without	  overstating	  benefits.	  	  
Protected	  health	  information	  including	  name,	  address,	  telephone	  number,	  e-­‐mail	  
address,	  medical	  record	  number,	  birth	  date,	  admission	  date,	  and	  discharge	  date	  was	  





devices.	  	  After	  the	  study,	  all	  identifiable	  information	  will	  be	  removed	  from	  the	  stored	  
data.	  
Student	  responsibilities	  
The	  medical	  student’s	  responsibilities	  in	  this	  study	  included	  study	  design	  as	  well	  as	  
those	  described	  above	  for	  the	  RA.	  The	  student	  assisted	  in	  the	  development	  of	  the	  
questionnaires	  that	  were	  administered	  to	  study	  subjects	  and	  also	  tested	  the	  Filemaker	  
application	  used	  to	  administer	  the	  survey.	  	  He	  developed	  the	  standardized	  script	  used	  to	  
approach	  potential	  subjects	  in	  the	  ED.	  	  	  He	  was	  solely	  responsible	  for	  recruiting	  and	  
consenting	  patients	  in	  the	  ED.	  	  Blood	  drawing	  responsibilities	  were	  split	  between	  the	  
medical	  student	  and	  nurses	  in	  the	  ED.	  	  The	  medical	  student	  collected	  patient	  urine.	  	  He	  
labeled	  all	  of	  the	  samples,	  filled	  out	  lab	  requisition	  paperwork,	  and	  transported	  all	  of	  
the	  samples	  to	  the	  YNHH	  laboratory.	  	  Here,	  lab	  staff	  processed	  the	  samples.	  	  The	  
student	  then	  transported	  all	  of	  these	  samples	  to	  a	  second	  laboratory	  for	  storage.	  	  After	  
storing	  the	  samples,	  the	  student	  followed	  up	  with	  patients	  via	  phone	  and	  email	  for	  up	  to	  
six	  months.	  He	  was	  also	  responsible	  for	  tracking	  that	  all	  follow-­‐ups	  were	  completed	  on	  
time.	  Once	  the	  follow-­‐up	  process	  was	  complete,	  he	  administered	  all	  patient	  incentives	  
(at	  time	  of	  enrollment	  and	  after	  follow-­‐up)	  in	  person	  or	  by	  mail.	  	  He	  logged	  all	  of	  the	  
automated	  recruitment	  pages	  he	  received	  and	  analyzed	  these	  data.	  	  The	  student	  was	  
also	  deeply	  involved	  in	  the	  process	  of	  selecting	  an	  appropriate	  machine-­‐learning	  model	  







We	  reached	  our	  goal	  of	  recruiting	  twelve	  concussion	  patients	  in	  the	  study.	  	  	  
Additionally,	  we	  enrolled	  twelve	  age-­‐	  and	  gender-­‐	  matched	  controls	  with	  isolated	  
extremity	  injuries	  sustained	  during	  recreational	  activity	  not	  involving	  the	  head.	  	  
Demographic,	  mechanism/timing	  of	  injury,	  and	  past	  medical	  history	  characteristics	  are	  
described	  in	  Table	  4.	  Ages	  and	  genders	  of	  patients	  were	  closely	  matched,	  at	  an	  average	  
of	  about	  16	  years	  old	  and	  2/12	  (17%)	  female	  in	  both	  the	  head	  injury	  and	  control	  groups.	  	  
Most	  patients	  were	  white	  (non-­‐Hispanic).	  	  Socioeconomically,	  patients	  were	  almost	  
evenly	  split	  between	  private	  insurance	  and	  Medicaid.	  	  	  Football	  injuries	  were	  the	  most	  
common	  cause	  of	  potentially	  eligible	  head	  injury	  pages	  at	  9/39	  (23%),	  while	  basketball	  
was	  the	  most	  common	  cause	  of	  potentially	  eligible	  control	  pages	  at	  8/27	  (30%)	  (Table	  
4).	  
Subject	  flow	  
Out	  of	  the	  24	  total	  subjects	  in	  the	  study,	  sixteen	  were	  recruited	  using	  automated	  
paging	  (Figure	  6).	  	  The	  vast	  majority	  of	  pages,	  483/549	  (88%),	  were	  for	  ineligible	  
subjects.	  	  These	  patients	  had	  a	  chief	  complaint	  of	  “head	  injury”,	  but	  did	  not	  meet	  
inclusion/exclusion	  criteria	  (e.g.	  no	  LOC/confusion/amnesia,	  non-­‐recreational	  injury,	  or	  
injury	  occurring	  more	  than	  six	  hours	  before	  ED	  presentation).	  	  Most	  ineligible	  patients	  
had	  several	  reasons	  for	  exclusion,	  making	  a	  detailed	  breakdown	  of	  these	  patients	  
became	  very	  cumbersome	  for	  a	  single	  RA	  to	  complete.	  	  Consequently,	  that	  analysis	  was	  
foregone	  in	  this	  thesis.	  	  There	  were	  five	  eligible	  potential	  subjects	  who	  were	  approached	  





enrollment	  refusal	  (n=2),	  followed	  by	  general	  disinterest	  (n=2)	  and	  distress	  from	  a	  
vasovagal	  episode	  (n=1).	  
Recruitment	  optimization	  
In	  Phase	  1	  of	  recruitment,	  ED	  staff	  informed	  the	  RA	  of	  potentially	  eligible	  patients	  
via	  telephone.	  	  In	  Phase	  1,	  ED	  staff	  did	  not	  identify	  any	  eligible	  patients;	  fourteen	  
potentially	  eligible	  patients	  were	  identified	  via	  EHR	  query.	  For	  this	  query,	  the	  EHR	  was	  
retrospectively	  searched	  for	  all	  patients	  aged	  13-­‐25	  who	  presented	  to	  the	  YNHH	  ED	  with	  
a	  chief	  complaint	  of	  head	  injury	  during	  Phase	  1.	  	  Of	  these	  patients,	  the	  ones	  who	  met	  
inclusion/exclusion	  criteria	  were	  deemed	  potentially	  eligible.	  	  In	  Phases	  2	  and	  3,	  the	  EHR	  
identified	  183	  potentially	  eligible	  head	  injury	  patients	  (previous	  figure	  of	  549	  total	  pages	  
includes	  pages	  for	  controls)	  of	  which	  39	  were	  eligible	  (Table	  5).	  Patient	  identification	  
rate	  improved	  from	  0/14	  (0.00±0.00)	  to	  39/183	  (0.21±0.06)	  (p<0.001)	  with	  EHR-­‐
generated	  notification.	  In	  Phase	  2	  (pre-­‐incentive),	  3/8	  patients	  approached	  in	  the	  ED	  
were	  enrolled;	  in	  Phase	  3	  (post-­‐incentive)	  8/8	  eligible	  patients	  were	  enrolled	  (Table	  5).	  
Enrollment	  rate	  improved	  from	  0.38±0.43	  to	  1±0.00	  	  (p=0.01)	  with	  financial	  incentives.	  	  
Non-­‐enrolled	  patients	  did	  not	  differ	  significantly	  from	  enrolled	  patients	  in	  mean	  age	  
(16.80	  vs.	  16.23,	  p=.64)	  or	  percentage	  of	  female	  patients	  (20%	  vs.	  17%,	  p=.88).	  	  
Enrollment	  rate	  was	  used	  instead	  of	  recruitment	  rate	  (i.e.	  patients	  recruited/month)	  
because	  recruitment	  was	  dependent	  on	  RA	  availability.	  
When	  were	  subjects	  recruited?	  
Enrollment	  began	  August	  7th,	  2015.	  By	  April	  14th	  2016,	  all	  twelve	  head	  injury	  patients	  





unmatched	  head	  injury	  patients.	  	  During	  the	  initial	  paging	  period,	  the	  RA	  received	  37/66	  
(56%)	  of	  pages	  for	  eligible	  patients	  on	  weekends	  -­‐	  Friday,	  Saturday,	  or	  Sunday	  -­‐	  and	  
44/66	  (66%)	  of	  potentially	  eligible	  pages	  were	  received	  at	  night	  -­‐	  6pm	  to	  5am	  (Table	  6).	  	  
In	  total,	  53/66	  (80%)	  of	  pages	  for	  potentially	  eligible	  patients	  were	  received	  on	  
weekends	  and/or	  nights.	  Of	  the	  nine	  eligible	  football-­‐related	  concussion	  pages,	  eight	  
(89%)	  occurred	  during	  the	  months	  of	  September	  and	  October,	  with	  the	  lone	  exception	  
occurring	  on	  November	  1st.	  	  
Proteomic	  samples	  
Blood	  and	  urine	  samples	  were	  collected	  from	  all	  24	  of	  the	  enrolled	  patients	  and	  
stored	  as	  described	  earlier	  in	  this	  document.	  	  All	  of	  these	  samples	  were	  usable	  for	  future	  
proteomic	  analysis.	  
Concussive	  symptom	  data	  
Among	  the	  twelve	  concussion	  subjects,	  three	  reported	  LOC,	  six	  reported	  post-­‐
concussive	  amnesia,	  seven	  reported	  feeling	  confused,	  and	  ten	  reported	  feeling	  dazed.	  	  
All	  of	  these	  patients	  also	  reported	  other	  concussive	  symptoms,	  including	  headache,	  
difficulty	  concentrating,	  and	  confusion	  (Table	  7).	  	  Based	  on	  the	  U.S.	  Military	  
Neurobehavioral	  Checklist,	  all	  twelve	  subjects	  remained	  symptomatic	  at	  24-­‐72	  hours,	  
three	  were	  symptom-­‐free	  at	  one	  week,	  eight	  were	  symptom-­‐free	  at	  one	  month,	  nine	  
were	  symptom-­‐free	  at	  three	  months,	  and	  ten	  were	  symptom-­‐free	  at	  six	  months	  with	  







In	  this	  prospective	  cohort	  pilot	  and	  feasibility	  study	  of	  twelve	  adolescent	  athletes	  
with	  concussion	  and	  age-­‐	  and	  gender-­‐matched	  controls,	  we	  found	  that	  identification	  
and	  enrollment	  of	  patients	  was	  significantly	  improved	  by	  the	  implementation	  of	  
automated	  EHR	  paging	  and	  additionally	  through	  patient	  incentives	  provided	  at	  the	  time	  
of	  enrollment	  and	  upon	  completion	  of	  follow-­‐up	  surveys.	  
Generalizability	  
The	  protocol	  demonstrated	  in	  this	  pilot	  study	  shows	  potential	  for	  use	  in	  future	  
concussion	  biomarker	  discovery	  projects.	  	  Automated	  pages	  are	  practical	  because	  they	  
do	  not	  rely	  on	  busy	  ED	  staff	  to	  identify	  patients	  and	  cost-­‐effective	  because	  medical	  
students	  can	  respond	  to	  evening	  pages	  while	  fulfilling	  daytime	  commitments.	  	  	  Indeed,	  
given	  the	  demanding	  nature	  of	  the	  ED	  environment	  and	  the	  typically	  off-­‐hours	  
presentation	  of	  head	  injury	  patients,	  automated	  pages	  and	  financial	  incentives	  could	  be	  
the	  preferred	  recruitment	  strategy	  for	  smaller	  concussion	  biomarker	  discovery	  projects.	  	  
To	  optimize	  recruitment,	  larger,	  funded	  studies	  should	  plan	  and	  budget	  to	  preferentially	  
staff	  RAs	  on	  nights	  and	  weekends.	  
Evidence	  of	  feasibility	  
We	  conducted	  our	  feasibility	  study	  in	  accordance	  to	  the	  principles	  outlined	  by	  
Bowen	  et	  al.(72)	  With	  “practicality”,	  we	  examined	  the	  performance	  of	  our	  recruitment	  
strategy	  in	  the	  time-­‐	  and	  resource-­‐strained	  setting	  of	  a	  busy	  ED.	  	  In	  phase	  one	  of	  





eligible	  patients.	  A	  clear	  majority	  of	  our	  eligible	  patients	  also	  presented	  on	  nights	  and	  
weekends,	  proving	  “camping”	  in	  the	  ED	  for	  long	  blocks	  of	  time	  as	  an	  inefficient	  and	  
unreasonable	  recruitment	  strategy.	  	  Automated	  EHR	  paging	  significantly	  improved	  
patient	  identification	  and	  alerted	  the	  RA	  about	  eligible	  patients	  during	  all	  hours.	  
However,	  many	  eligible	  patients	  still	  lacked	  motivation	  to	  participate	  after	  this	  first	  
adjustment.	  	  With	  a	  focus	  on	  “adaptation”,	  we	  added	  gift	  card	  incentives	  to	  the	  study.	  	  
This	  small	  amount	  of	  compensation	  incentivized	  eligible	  patients	  to	  enroll	  in	  the	  study	  –	  
even	  those	  with	  an	  aversion	  to	  needlesticks	  –and	  complete	  the	  follow-­‐up	  protocol.	  	  Our	  
study	  demonstrated	  “efficacy”	  because	  we	  reached	  our	  recruitment	  goal	  within	  the	  
one-­‐year	  goal	  we	  defined	  for	  ourselves.	  The	  efficacy	  of	  the	  strategy	  is	  limited	  mainly	  by	  
the	  fact	  that	  the	  cohort	  of	  24	  patients	  was	  a	  convenience	  sample.	  	  At	  times,	  the	  RA	  was	  
available	  to	  screen	  every	  page	  he	  received,	  but	  at	  other	  times,	  the	  RA	  was	  not	  around	  
the	  hospital	  and	  could	  not	  screen	  patients.	   	  
Limitations	  
Concussion	  patients	  and	  controls	  in	  this	  study	  were	  young,	  healthy,	  and	  age-­‐	  and	  
gender-­‐matched,	  likely	  creating	  an	  environment	  that	  minimized	  baseline	  proteomic	  
variability.	  	  Though	  our	  age-­‐	  and	  gender-­‐matched	  controls	  were	  adequate	  for	  use	  in	  a	  
small	  pilot	  study,	  there	  may	  still	  be	  proteomic	  variability	  between	  individuals	  that	  could	  
not	  be	  accounted	  for	  with	  this	  matching	  method.	  The	  ideal	  control	  group	  would	  consist	  
of	  pre-­‐season	  samples	  from	  the	  same	  athletes,	  but	  this	  would	  require	  banking	  
specimens	  from	  a	  large	  population	  of	  athletes	  in	  anticipation	  of	  a	  potential	  head	  injury.	  





proteomic	  data.	  	  Though	  this	  protocol	  has	  the	  potential	  to	  identify	  acute	  (<6	  hours)	  
biomarkers,	  it	  will	  not	  track	  the	  trend	  of	  biomarker	  levels	  over	  time.	  	  	  
One	  of	  the	  principal	  limitations	  of	  this	  study	  was	  its	  sample	  size.	  	  As	  a	  pilot	  study,	  
sample	  sizes	  were	  determined	  by	  practical	  and	  financial	  limitations	  rather	  than	  power	  
calculations.	  	  Furthermore,	  there	  was	  no	  binary	  hypothesis	  to	  test,	  making	  power	  
calculations	  even	  less	  appropriate.	  It	  is	  difficult	  to	  infer	  that	  the	  biomarkers	  identified	  in	  
this	  pilot	  study	  are	  in	  fact	  associated	  with	  mTBI.	  	  However,	  with	  candidate	  biomarkers	  
identified,	  the	  performance	  of	  the	  biomarker	  panel	  can	  be	  tested	  in	  a	  larger	  study.	  That	  
said,	  the	  proteomic	  data	  will	  be	  large	  and	  important	  biomarkers	  have	  been	  identified	  
with	  a	  small	  sample	  sizes,	  as	  low	  as	  in	  the	  30’s	  in	  existing	  aptamer	  studies.(65)	  
This	  study	  was	  limited	  by	  its	  use	  of	  a	  single	  RA.	  	  The	  RA	  missed	  far	  more	  eligible	  
patients	  than	  he	  was	  available	  to	  recruit.	  	  A	  larger	  study	  would	  benefit	  from	  a	  team	  of	  
RA’s	  and	  more	  ED	  coverage.	  	  Another	  recruitment-­‐related	  limitation	  of	  this	  study	  was	  
the	  large	  amount	  of	  head	  injury	  pages	  required	  to	  find	  eligible	  patients.	  	  To	  improve	  the	  
yield	  of	  the	  pages,	  nursing	  triage	  notes	  would	  have	  to	  be	  coded	  in	  addition	  to	  chief	  
complaints.	  
Another	  limitation	  of	  the	  study	  is	  the	  self-­‐reported	  follow-­‐up	  surveys	  used	  to	  
determine	  the	  duration	  of	  concussion	  symptoms.	  These	  surveys	  are	  subject	  to	  recall	  
bias.	  	  One	  could	  also	  argue	  that	  the	  inclusion	  of	  a	  post-­‐follow-­‐up	  incentive	  could	  
encourage	  subjects	  to	  under-­‐report	  symptoms.	  	  This	  problem	  could	  be	  circumvented	  
with	  the	  use	  of	  formal	  neuropsychiatric	  follow-­‐up	  visits,	  though	  such	  intensive	  follow-­‐up	  






EHR-­‐based	  paging	  and	  financial	  incentives	  for	  participation	  increased	  subject	  
identification	  and	  enrollment	  rates	  to	  inform	  and	  optimize	  the	  enrollment	  and	  
recruitment	  strategies	  for	  the	  eventual	  larger	  study.	  Our	  next	  step	  will	  be	  developing	  an	  
extensive	  profile	  of	  changes	  in	  the	  blood	  proteome	  following	  concussion.	  





Tables and Figures  
Table	  1:	  CDC	  -­‐	  Concussion	  signs	  and	  symptoms	  
Signs	   Symptoms	  
• Appears	  dazed	  or	  stunned	  
•	  Is	  confused	  about	  events	  
•	  Answers	  questions	  slowly	  
•	  Repeats	  questions	  
•	  Can’t	  recall	  events	  prior	  
to	  the	  hit,	  bump,	  or	  fall	  
•	  Can’t	  recall	  events	  after	  
the	  hit,	  bump,	  or	  fall	  
•	  Loses	  consciousness	  
(even	  briefly)	  




•	  Difficulty	  thinking	  clearly	  
•	  Difficulty	  concentrating	  or	  
remembering	  
•	  Feeling	  more	  slowed	  
down	  
•	  Feeling	  sluggish,	  hazy,	  










•	  Headache	  or	  “pressure”	  
in	  head	  
•	  Nausea	  or	  vomiting	  
•	  Balance	  problems	  or	  
dizziness	  
•	  Fatigue	  or	  feeling	  tired	  
•	  Blurry	  or	  double	  vision	  
•	  Sensitivity	  to	  light	  or	  
noise	  
•	  Numbness	  or	  tingling	  
•	  Does	  not	  “feel	  right”	  
Sleep:	  
•	  Drowsy	  
•	  Sleeps	  less	  than	  usual	  
•	  Sleeps	  more	  than	  usual	  
•	  Has	  trouble	  falling	  asleep	  
Source:	  Centers	  for	  Disease	  Control	  and	  Prevention,	  Heads	  Up:	  Concussion	  in	  High	  





Table	  2:	  Graduated	  return	  to	  play	  protocol	  
Stage	   Functional	  Exercise	   Objective	  
No	  activity	   Symptom-­‐limited	  physical	  
and	  cognitive	  rest	  
Recovery	  
Light	  aerobic	  exercise	   Walking,	  swimming	  or	  
stationary	  cycling	  keeping	  
intensity	  <70%	  maximum	  
permitted	  heart	  rate	  
Increase	  heart	  rate	  
Sport-­‐specific	  exercise	   Skating	  drills	  in	  ice	  hockey,	  
running	  drills	  in	  soccer.	  No	  
head	  impact	  activities	  
Add	  movement	  
Non-­‐contact	  training	  drills	   Progression	  to	  more	  
complex	  training	  drills,	  for	  
example,	  passing	  drills	  in	  
football	  and	  ice	  hockey.	  
May	  start	  progressive	  
resistance	  training	  
Exercise,	  co-­‐ordination	  and	  
cognitive	  load	  
Full	  contact	  practice	   Following	  medical	  
clearance	  participate	  in	  
normal	  training	  activities	  
Restore	  confidence	  and	  
assess	  functional	  skills	  by	  
coaching	  staff	  





Source:	  Consensus	  Statement	  on	  Concussion	  in	  Sport	  4th	  International	  Conference	  on	  
Concussion	  in	  Sport.(2)	  Adapted	  from	  Silvia	  Bressan	  and	  Franz	  E.	  Babi	  Diagnosis	  and	  
Management	  of	  Pediatric	  Concussion.(3)	  
	  
	  
Figure	  1:	  A	  graphical	  representation	  of	  a	  decision	  tree.	  	  This	  example	  sorts	  into	  four	  














Figure	  3:	  A	  graphical	  representation	  of	  artificial	  neural	  networks	  and	  the	  layers	  
involved	  in	  the	  generation	  of	  a	  model.	  
	  
Table	  3:	  Chief	  complaints	  included	  in	  the	  EHR	  query	  for	  control	  subjects	  
• ankle	  injury	  
• ankle	  pain	  
• ankle	  
swelling	  
• arm	  injury	  
• arm	  pain	  
• arm	  swelling	  
• clavicle	  
injury	  
• clavicle	  pain	  
• clavicle	  
swelling	  
• elbow	  injury	  
• elbow	  pain	  
• hand	  injury	  
• hand	  pain	  
• hand	  
swelling	  
• hip	  injury	  
• hip	  pain	  












• wrist	  injury	  
• wrist	  pain	  
• wrist	  
swelling	  
• leg	  injury	  
• leg	  pain	  




• finger	  injury	  
• finger	  pain	  
• finger	  
swelling	  
• foot	  injury	  
• foot	  pain	  
• foot	  swelling	  
	  
• joint	  injury	  
• joint	  pain	  
• joint	  
swelling	  
• knee	  injury	  




• thumb	  pain	  
• thumb	  
swelling	  
• toe	  injury	  
• toe	  pain	  
• toe	  swelling	  
• wrist	  injury	  












Figure	  4:	  Sample	  patient	  data	  entry	  screen	  on	  tablet	  






Figure	  5.	  Screen	  capture	  from	  online	  follow-­‐up	  survey	  with	  the	  U.S.	  Military	  












Table	  4:	  Baseline	  characteristics	  of	  recruits	  
Characteristic	   Head	  Injury	  
(n=12)	  
Control	  (n=12)	   P-­‐valueA	  
Age	  (yr),	  mean±SD	   16.23±1.65	   16.46±1.76	   0.74	  
Male	  (%)	   10	  (83)	   10	  (83)	   .99	  
Race	   	   	   	  
	  	  	  	  	  	  	  	  	  	  White	  (%)	   9	  (75)	   10	  (83)	   0.85	  
	  	  	  	  	  	  	  	  	  	  Black	  (%)	   3	  (25)	   4	  (33)	   0.67	  
	  	  	  	  	  	  	  	  	  	  Other	   0	  (0)	   0	  (0)	   0.99	  
Ethnicity	   	   	   	  
	  	  	  	  	  	  	  	  	  	  Hispanic	  (%)	   2	  (17)	   2	  (17)	   0.99	  
	  	  	  	  	  	  	  	  	  	  Non-­‐Hispanic	  (%)	   10	  (83)	   10	  (83)	   0.99	  
Insurance	  Type	   	   	   	  
	  	  	  	  	  	  	  	  	  	  Private/HMO	  (%)	   7	  (58)	   6	  (50)	   0.70	  
	  	  	  	  	  	  	  	  	  	  Medicaid	  (%)	   5	  (42)	   6	  (50)	   0.70	  
	  	  	  	  	  	  	  	  	  	  Other/Self-­‐pay	  (%)	   0	  (0)	   0	  (0)	   0.99	  
Inciting	  Recreational	  Activity	   	   	   	  
	  	  	  	  	  	  	  	  	  	  Football	  (%)	   2	  (17)	   0	  (0)	   0.15	  
	  	  	  	  	  	  	  	  	  	  Basketball	  (%)	   2	  (17)	   3	  (25)	   0.63	  
	  	  	  	  	  	  	  	  	  	  Wrestling	  (%)	   0	  (0)	   3	  (25)	   0.08	  





	  	  	  	  	  	  	  	  	  	  Soccer	  (%)	   1	  (8)	   0	  (0)	   0.34	  
	  	  	  	  	  	  	  	  	  	  Floor	  Hockey	  (%)	   1	  (8)	   0	  (0)	   0.34	  
	  	  	  	  	  	  	  	  	  	  Volleyball	  (%)	   0	  (0)	   1	  (8)	   0.34	  
	  	  	  	  	  	  	  	  	  	  Lacrosse	  (%)	   1	  (8)	   0	  (0)	   0.34	  
	  	  	  	  	  	  	  	  	  	  Other	  (%)	   2	  (17)	   3	  (25)	   0.63	  
Chronic	  conditions	   	   	   	  
	  	  	  	  	  	  	  	  	  	  Prior	  Concussion(s)	  (%)	   3	  (25)	   3	  (25)	   0.99	  
	  	  	  	  	  	  	  	  	  	  Asthma	  (%)	   4	  (33)	   3	  (25)	   0.67	  
	  	  	  	  	  	  	  	  	  	  Migraines	  (%)	   1	  (8)	   1	  (8)	   0.99	  
	  	  	  	  	  	  	  	  	  	  ADHD	  (%)	   0	  (0)	   2	  (17)	   0.17	  
	  	  	  	  	  	  	  	  	  	  Extremity	  Fracture	  (%)	   2	  (17)	   2	  (17)	   0.99	  
A	  P-­‐value	  calculated	  with	  two-­‐sided	  t-­‐test	  (homoscedascity/heteroscedascity	  






Figure	  6:	  Patient	  recruitment	  and	  enrollment	  flowchart	  	  
A	  1	  head	  injury	  subject	  and	  7	  controls	  were	  enrolled	  without	  the	  EHR	  paging	  system	  
	  
	  
Total	  Pages	  received	  August	  
2015-­‐	  April	  2016 
(n	  =	  549) 
Did	  not	  meet	  
inclusion/exclusion	  criteria	  (n	  
=	  483) 
Total	  eligible	  (n	  =	  66) 
Patients	  missed 
(n	  =	  45) 
Total	  patients	  screened	  in	  
person 
(n	  =	  21) 
EnrolledA 
	  (n	  =	  16) 
Not	  Enrolled	   
(n	  =	  5) 
Head	  injuries 
	  (n	  =	  11) 
Controls 





Table	  5:	  Head	  injury	  recruitment	  by	  phase	  







IdentifiedB	   0	   66	   117	   183	  
EligibleC	   0	   17	   22	   39	  
RecruitedD	   0	   8	   8	   16	  
Enrolled	   0	   3	   8	   11	  
A	  Phase	  1	  –	  Notification	  by	  ER	  staff;	  Phase	  2	  –	  Automated	  EHR	  paging;	  Phase	  3	  –	  
Automated	  EHR	  paging	  with	  added	  incentives	  for	  subjects	  
B	  “Identified”	  patients	  were	  those	  with	  a	  chief	  complaint	  of	  “head	  injury”	  for	  whom	  the	  
RA	  received	  an	  EHR	  page.	  	  
C	  “Eligible”	  patients	  met	  inclusion/exclusion	  criteria	  after	  patient	  interview	  or	  EHR	  
review	  (if	  RA	  was	  unavailable	  and	  patient	  was	  missed).	  	  Fourteen	  such	  patients	  in	  Phase	  
1	  were	  identified	  retrospectively.	  
















Table	  6:	  Night	  and	  weekend	  head	  injury	  pages	  
Time	  of	  page	   Head	  Injury	  
(n=39)	  
Control	  (n=27)	   p-­‐valueA	  
	  	  	  	  	  	  	  	  	  	  6am	  –	  5pm	  (%)	   9	  (23)	   13	  (48)	   .03	  
	  	  	  	  	  	  	  	  	  	  5pm	  –	  6am(%)	   30	  (77)	   14	  (52)	   .03	  
	  	  	  	  	  	  	  	  	  	  	  Friday,	  Saturday,	  Sunday	   21	  (54)	   16	  (59)	   .67	  
	  	  	  	  	  	  	  	  	  	  	  Monday	  -­‐	  Thursday	   18	  (46)	   11	  (41)	   .67	  






















Table	  7:	  Clinical	  outcomes	  from	  online	  survey	  (all	  data	  are	  %	  followed	  by	  standard	  
deviation,	  n=12	  for	  all	  calculations)	  
	  
Symptom	   <6	  hrs	   24-­‐72	  
hours	  	  
1	  week	  A	   1	  month	   3	  months	  
	  
6	  months	  
Feeling	  Dizzy	   83.3 
(10.8)	  

































Headache	   91.7 
(8.0)	  



































































0.0 (0.0)	   8.3 (8.0)	   0.0 (0.0)	  
Change	  in	  
taste	  
NA	   16.7 
(10.8)	  
0.0 (0.0)	   0.0 (0.0)	   8.3 (8.0)	   0.0 (0.0)	  
Appetite	  
Change	  
NA	   16.7 
(10.8)	  
0.0 (0.0)	   16.7 
(10.8)	  











8.3 (8.0)	   0.0 (0.0)	  





















































8.3 (8.0)	   0.0 (0.0)	  
Feeling	  
Anxious	  















8.3 (8.0)	   8.3 (8.0)	   0.0 (0.0)	  














8.3 (8.0)	   16.7 
(10.8)	  
0.0 (0.0)	  
Ringing	  in	  the	  
ears	  

















8.3 (8.0)	  B	  
A	  One-­‐week	  follow-­‐up	  from	  one	  patient	  was	  filled	  in	  with	  duplicated	  one-­‐month	  follow-­‐
up	  data	  from	  the	  same	  patient	  (subject	  missed	  one-­‐week	  follow-­‐up	  but	  was	  compliant	  
thereafter)	  
B	  Two	  subjects	  were	  lost	  to	  follow-­‐up	  after	  3-­‐month	  follow-­‐up.	  One	  remained	  
symptomatic	  at	  6	  months	  (confirmed	  with	  EHR	  query).	  This	  patient	  was	  included	  in	  the	  
“symptoms	  unresolved”	  calculation,	  but	  none	  of	  the	  other	  calculations.	  The	  status	  of	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Appendix: Recruitment script 
 
1. Overview 
Hi, my name is (name), and I am working as a research assistant in the emergency 
department.  I am not a part of you care team today, but I am helping conduct a study on 
head injuries called the COMPETE study.  It is a study involving young athletes like you 
that have had head injuries.  The hope is that the project will lead to the development of 
a quick blood or urine test that will be able to help us find out which head injuries are 
more serious than others.  This could, for example, allow football coaches to quickly 
judge if and when it is safe to allow players to return to the field after a head injury.  It is 
an exciting study, and it has the potential to have a huge impact in both sports and the 
military.  Involvement in the study requires a minimal commitment.  If you agree to 
participate in the study, we would collect quick blood and urine samples today, and over 
the next 6 months, you would fill out a series of very quick surveys about how you’re 
feeling.  I would call you 6 times over the next 6 months and have a 5-minute 
conversation about how you’re feeling. 
 
2a (older adolescents/adults). 
Participation in this study is completely voluntary.   If you choose to not participate, it will 
in no way affect the care you are receiving.  If you choose to enroll in the study but you 
change your mind, you are free to withdraw at any time.  Withdrawing from the study 
won’t affect your care or your relationship with any of the doctors at XXXXXXX Hospital.   
Again, what is involved in the study is the collection of blood [If already drawn, say that it 
will not require an additional stick] and urine from you today, and after that, a symptom 
journal to document your symptoms, and six five-minute phone calls over the next few 
months.  You would not have to come back to the hospital to follow up or meet with any 
of the doctors involved with the study.   
 
Female participant (alone): 
Pregnancy causes a lot of changes in blood chemistry, so we ask that female 
participants of childbearing age also take a pregnancy test.  The results of the test will 
be kept confidential, but a positive test would disqualify you from the study.  Additionally, 
if you were to become pregnant during the study, we would have to withdraw you.  So, if 
there is a reasonable chance that you are pregnant now or may become pregnant soon, 
we would advise that you not participate. 
This is study with very minimal risk to you.  Some of the rare risks of blood draws include 





pressure would be applied afterward to minimize infection and bleeding.  The other small 
risk would be leakage of personal information.  I would like to assure you that we make 
every effort to keep the information that we collect confidential.  We will not share your 
information with others unless there is a rare situation where the law requires us to share 
in the information. If the data is published, any information that can identify you will 
remain confidential. 
 
Do you have any questions? 
 
Okay, here is a consent form for you to look over and sign.  It goes over the details of 




Your child’s participation in this study is completely voluntary.   If you choose to not 
participate, it will in no way affect the care he/she is receiving.  If you choose to enroll in 
the study but change your mind, you are free to withdraw at any time.  Withdrawing from 
the study won’t affect your care or your relationship with any of the doctors at XXXXXXX 
Hospital.   
 
Again, what is involved in the study is the collection of blood [If already drawn, say that it 
will not require an additional stick] and urine from your child today, a symptom journal to 
document his/her symptoms with him/her, and six five-minute phone calls over the next 
few months.  I will call you at a time that is good for both you and your child and we will 
quickly talk about your child’s symptoms.  Neither your child nor you would be required 
to come back to the hospital to follow up or meet with any of the doctors involved with 
the study.   
 
To Female participant (Gauge interest.  Then ask parent to leave.): 
Pregnancy causes a lot of changes in blood chemistry, so we ask that female 
participants of childbearing age also take a pregnancy test.  The results of the test will 
only be known to you, but in the event that the test is positive, we would counsel you on 
seeking appropriate healthcare and the support of adults around you.  If you were to 
become pregnant during the study, we would also have to withdraw you from the study.  
So, if there is a reasonable chance that you are pregnant now or may become pregnant 






(Allow parent back in room.) 
 
This is study with very minimal risk to your child.  Some of the rare risks of blood draws 
include bleeding and infection, but a sterile needle would be used to draw the blood and 
pressure would be applied afterward to minimize infection and bleeding.  The other small 
risk would be leakage of personal information.  I would like to assure you that we make 
every effort to keep the information that we collect confidential.  We will not share your 
information with others unless there is a rare situation where the law requires us to share 
in the information. If the data is published, any information that can identify you will 
remain confidential. 
 
Do you have any questions? 
 
Okay, here is a consent form for you to look over and sign.  We also have a consent 
form for your child. It goes over the details of the study.  Whenever you are ready, you 
can sign the last page of the form, and we can get started. 
 
3. Closing. 
Thank you so much for your time.  It was a pleasure meeting you.  Although I am not a 
part of your care team, I can certainly convey any of your concerns to your team to make 
sure that all of your needs are met.  I will be back with your nurse shortly. 
 
